Circulation - McMaster Experts

publication venue for

Exploring the Experiences of Substitute Decision Makers with Exception to Consent in a Pediatric Resuscitation Trial 2024
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD 2024
Lipoprotein(a) and Oxidized Phospholipids on Lipoproteins and Cardiovascular Outcomes in Patients With Chronic Coronary Syndrome Treated With Colchicine 2023
Residual Stroke Risk Among Atrial Fibrillation Patients Treated With Warfarin or Novel Oral Anticoagulants: A Patient Level MetaAnalysis From Combine AF 2023
A Patient-Risk Based Health System Intervention for Acute Heart Failure Care: The Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial 2022
Electrocardiographic Changes After Cardiac Surgery and 30-Day Mortality 2022
Interim Results of a Phase 2 Study With RBT-1 Evaluating Postoperative Course in Patients Undergoing Elective CABG/Valve Surgery on Cardiopulmonary Bypass 2022
Alcohol Consumption and Arrhythmia Recurrence After Atrial Fibrillation Ablation: A Systematic Review and Meta-Analysis 2022
Alcohol Consumption and Cardiovascular Outcomes in Patients With Atrial Fibrillation; a RE-LY AF Registry Analysis 2022
Causes of Death in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization: Insights From Voyager Pad 2022
Efficacy and Safety of NOACs vs. Warfarin Across the Continuous Range of Body Mass Index and Body Weight: Insights From COMBINE-AF 2022
Lower May Not Be Better: Systolic Blood Pressure and Risk of Major Adverse Limb Events in Patients With Symptomatic Peripheral Artery Disease After Revascularization: Insights From Voyager Pad 2022
Mineralocorticoid Receptor Antagonists and Atrial Fibrillation: A Systematic Review and Meta-Analysis 2022
Sex Differences in the Etiology and Burden of Heart Failure Across the Sociodemographic Index: Analysis of 204 Countries and Territories, 1990-2019 2022
Impact of Sodium-Glucose Co-Transporter-2 Inhibition on the Efficacy and Safety of the Glucagon-like Peptide-1 Receptor Agonist Efpeglenatide in Type 2 Diabetes 2021
Impact of Sodium-Glucose Co-Transporter-2 Inhibition on the Efficacy and Safety of the Glucagon-like Peptide-1 Receptor Agonist Efpeglenatide in Type 2 Diabetes 2021
Risk Profile and Efficacy and Safety of Rivaroxaban in Patients Undergoing Revascularization For Claudication: Insights From VOYAGER PAD 2021
Risk Profile and Efficacy and Safety of Rivaroxaban in Patients Undergoing Revascularization For Claudication: Insights From VOYAGER PAD 2021
Association of Eligibility for a Sodium-Glucose Co-Transporter 2 Inhibitor and Cardiovascular Outcomes in Patients with Atrial Fibrillation 2021
Bone Morphogenetic Protein 10-A Novel Biomarker of Ischemic Stroke in Patients With Atrial Fibrillation 2021
Depict Analysis Suggests Enrichment of Heart Valve Tissue Expression in African Rheumatic Heart Disease Patients From the RHDGen GWAS Study Cohort 2021
Estimating Cardiovascular and Limb Benefits of Combined Contemporary Risk Reduction Therapies in Patients with Symptomatic Peripheral Artery Disease: An Analysis of Randomized Controlled Trials 2021
NT-proBNP is Associated with Stroke, Heart Failure Hospitalizations, and Death in Patients with Atrial Fibrillation Without Oral Anticoagulation Regardless of Heart Rhythm 2021
Non-Pharmacological Interventions to Improve Electrical Cardioversion Success in Patients With Atrial Fibrillation: A Scoping Review 2021
A Polypill for Primary Prevention of Cardiovascular Disease in Intermediate Risk People: Results of the International Polycap Study (TIPS)-3 2020
Efficacy and Safety of Rivaroxaban in Patients With PAD Undergoing Lower Extremity Revascularization for Critical Limb Ischemia: Insights From VOYAGER PAD 2020
Rivaroxaban Plus Aspirin versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From Voyager PAD 2020
A Machine Learning Approach to Predicting Risk of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors 2020
Abstract 14410: A Machine Learning Approach to Predicting Risk of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors 2020
Burden of Cardiovascular or Fatal Outcomes in People With Type 2 Diabetes and Cardiovascular Risk Factors Treated With Dulaglutide a Post Hoc Analysis From the Rewind Trial 2020
Outcomes of Heart Failure in Hypoplastic Left Heart Syndrome and the Impact of Recovery 2020
Are the Beneficial Cardiovascular Effects of Glucagon-Like Peptide 1 Receptor Agonists in Diabetic Patients Metabolically Mediated? 2019
Contrasting Patterns of Risk Factors, Treatments and Outcomes in Women and Men in Those With and Without Prior Cardiovascular Disease in High (H), Middle (M), and Low-Income Countries (LIC) 2019
Effect of Patient-Centered Transitional Care Services in Patients Hospitalized for Heart Failure: Clinical and Sex Specific Outcomes of the PACT-HF Randomized Clinical Trial 2019
Rivaroxaban Plus Aspirin versus With Aspirin in Patients With Prior Percutaneous Coronary Intervention (PCI): Insights From the COMPASS Trial 2019
Absence of Coronary Artery Disease by Coronary Angiography is Associated With a Lower Risk of Myocardial Infarction Than in the General Population 2019
Clinical Characteristics of Patients With Heart Failure Show a Continuum Across the Spectrum of Left Ventricular Ejection Fraction: A Substudy of the Patient-Centered Care Transitions in Heart Failure Randomized Clinical Trial 2019
Impact of Medical Management on Transplant-Free Survival in Pediatric Dilated Cardiomyopathy 2019
Kinetics of High-Sensitivity Cardiac Troponin I and T Following Symptom Onset in Non-ST-Segment Elevation Myocardial Infarction: It is Time to Revise the Textbooks 2019
Legacy of Lipid Lowering in Preventing Fatal and Non Fatal Cardiovascular Events in Individuals Without Cardiovascular Disease During 3 Years of Post -Trial Observation in the Hope 3 (Heart Outcomes Prevention Evaluation 3) Study 2019
Predictors of Left Ventricular Size and Function Normalization in Pediatric Dilated Cardiomyopathy Patients 2019
Pregnancy Outcomes in Women With Significant Valvular Heart Disease in Medium or Higher Human Development Index Countries: A Systematic Review and Meta-analysis 2019
Rivaroxaban Plus Aspirin versus With Aspirin in Patients With Prior Percutaneous Coronary Intervention (PCI): Insights From the COMPASS Trial 2019
Efficacy of Electronic Clinical Decision Support in Atrial Fibrillation: Results of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation [IMPACT-AF] 2018
Prehospital Opioid Administration to Acute Myocardial Infarction Patients: A Systematic Review 2018
GDF-15 is Associated With Major Bleeding and Death Independent of Geographic Regions in Patients With Atrial Fibrillation 2018
Genomic Architecture of Adverse Right Ventricular Remodeling in Tetralogy of Fallot 2018
Genomic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors 2018
Variations in Stepped Wedge Cluster Randomized Trial Design: Insights From the Patient-Centered Care Transitions in Heart Failure Trial 2018
The "Hub and Spoke" Model of Heart Function Care Achieves Quality Index Markers 2018
A Randomized Controlled Trial of Continued versus Interrupted Novel Oral Anti-Coagulant at the Time of Device Surgery (BRUISE CONTROL-2) 2017
Costs Impact Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial 2017
TRiCS III - An International Multicenter Randomized Trial of Transfusion Requirements in Cardiac Surgery 2017
Comparison of Cardiac Computerized Tomography Angiography and Transesophageal Echocardiography for Device Surveillance After Endovascular Left Atrial Appendage Closure 2017
Epidemiological Trends in Atrial Fibrillation in Europe: The EURObservational Research Programme in Atrial Fibrillation Pilot and Long-Term Registries and Euro Heart Survey on Atrial Fibrillation 2017
High-Sensitivity Cardiac Troponin I at Presentation in Patients With Suspected Acute Coronary Syndrome 2017
Idarucizumab in Dabigatran-Treated Patients Requiring Emergency Surgery or Intervention: Updated/Final Results From the RE-VERSE AD Study 2017
Impact of Rivaroxaban Alone or in Combination With Aspirin versus Aspirin in Preventing Graft Occlusion in Patients With CABG Surgery COMPASS CABG 2017
Intermittent Myocardial Stretch Elicits a Reduction in Left Ventricular Diastolic Compliance and Pathologic Characteristics of Heart Failure With Preserved Ejection Fraction in Swine 2017
Knowledge to Action: Rationale and Design of the Patient-Centred Care Transitions in Heart Failure (PACT-HF) Pragmatic Trial 2017
Marked Global Variability in Cost Effectiveness of Lipid-Lowering and Combination Antihypertensive Therapies in Primary Prevention: Analyses of the HOPE-3 Trial 2017
Phosphorylation of Acetylcoa Carboxylase by Ampk In Platelets Controls Thromboxane Generation, Dense Granules Secretion and Thrombus Formation 2017
Safety and Efficacy of Routine Defibrillation Testing at Time of Defibrillator Implantation: A Meta-analysis of Randomized-Controlled Trials 2017
Testosterone Levels and Risk for Cardiovascular Events - A Report From the ORIGIN (Outcome Reduction With an Initial Glargine Intervention) Trial 2017
Potential Mortality Reduction with Optimal Usage of sacubitril/valsartan Therapy for the Treatment of Heart Failure in Canada 2017
Potential Mortality Reduction with Optimal Usage of sacubitril/valsartan Therapy for the Treatment of Heart Failure in Canada 2017
Atrial Substrate Modification With Aggressive Blood Pressure Control to Prevent Atrial Fibrillation (SMAC AF) 2016
Idarucizumab For Dabigatran Reversal: Updated Results Of The Re-verse Ad Study 2016
Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patients With Cardiovascular Risk Factors: ASSERT II 2016
The Effect of Blood Pressure and Cholesterol Lowering on Cognition 2016
Comparison of Contemporary Bleeding Risk Scores in Patients With Non-Valvular Atrial Fibrillation Treated With Dabigatran or Warfarin: Insights From the RE-LY Trial 2016
Exception to Consent in Pediatric Resuscitation Research: Exploring the Experiences of Substitute Decision Makers 2016
Improved Treatment Satisfaction Independent of Stroke and Bleeding Risk Among Patients Transitioned From a Vitamin K Antagonist to Rivaroxaban: A XANTUS-ACTS Analysis 2016
Randomized Trial of Short vs Ultra Short Radial Artery Clamp Time Post Trans-radial Cardiac Catheterization 2016
Risk of Stroke Associated With Atrial Fibrillation After Non-cardiac Surgery: Insights From a Meta-analysis of Randomized Controlled Studies and Observational Studies 2016
Risk of Stroke Associated With Atrial Fibrillation After Non-cardiac Surgery: Insights From a Meta-analysis of Randomized Controlled Studies and Observational Studies 2016
The Impact of Dual Antiplatelet Therapy on Mortality: A Patient-Level Meta-Analysis 2016
The Impact of Dual Antiplatelet Therapy on Mortality: A Patient-Level Meta-Analysis 2016
The Impact of Smoking on Clinical Outcomes and the Role of Double-Dose versus Standard-Dose Clopidogrel Among Individuals With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention -Insights From the CURRENTOASIS 7 Trial 2016
Risk of Mortality According to Burden of Atrial Fibrillation: Results From a 60-year Cohort Study 2016
ANNEXA (TM)-R Part 2: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Sustained Reversal of Rivaroxaban-Induced Anticoagulation in Older Subjects by Andexanet Alfa (PRT064445), a Universal Antidote for Factor XA (FXA) Inhibitors 2015
The Efficacy and Safety of Varenicline, a Selective Alpha4beta2 Nicotinic Receptor Partial Agonist, for Smoking Cessation in Patients Hospitalized With Acute Coronary Syndrome: A Randomized Controlled Trial 2015
Atorvastatin for the Prevention of Major Vascular Events in Patients Undergoing Non-Cardiac Surgery: The LOAD-Pilot Randomized Clinical Trial 2015
Early Repolarization and Implantable Cardioverter Defibrillator Events in Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER) 2015
Efficacy and Safety of Dabigatran Compared With Warfarin in Patients With Atrial Fibrillation and Normal Renal Function Over Time: Insights From the RE-LY Trial 2015
Increasing QRS Duration Over Time Is Associated With Mortality and Morbidity in an Outpatient Heart Failure Population 2015
Plasma Metabolomic Profiles Differentiate Hemodynamic Subtypes of Pulmonary Hypertension 2015
Short-Term Changes in Carotid Artery Inflammation Measured by Positron Emission Tomography are Associated With Long Term Atherosclerosis Progression Measured by Magnetic Resonance Imaging 2015
Sub-clinical Atrial Fibrillation in Elderly Primary Care Patients Without Clinical Atrial Fibrillation 2015
Supplementation to Treat Antithrombin Deficiency Improves Sensitivity to Heparin, Anticoagulation and Decreased Thrombogenecity in Neonates and Infants Undergoing Cardiac Surgery With Cardiopulmonary Bypass 2015
The Prognostic Value of Insulin-like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Ejection Fraction: Results From Irbesartan in Heart Failure and Preserved Ejection Fraction (I-PRESERVE) Trial 2015
Epidemiology of Ischemic Stroke Subtypes Within the Mashhad Stroke Incidence Study (MSIS): A Population Based Study of Stroke in the Middle East 2015
ANNEXA (TM)-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Apixaban-Induced Anticoagulation in Older Subjects by Andexanet alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors 2014
Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent 2014
A Landmark Analysis of 30-day Mortality after Coronary Artery Bypass Surgery in Patients with Ischemic Heart Failure: Results of the Surgical Treatment for Ischemic Heart Failure (STICH) Trial 2014
Achieved Blood Pressure Targets and Cardiovascular Outcomes in Stable Ischemic Heart Disease: a Post Hoc Analysis from the COURAGE trial 2014
Burden of Coronary Atherosclerosis and Cardiovascular Events in Men and Women with Stable Ischemic Heart Disease 2014
Can Biomarkers Improve Risk Stratification of Atrial Fibrillation Patients? Analysis of 3578 Aspirin-treated Patients in ACTIVE and AVERROES 2014
Coronary Flow Velocity Reserve and Aortic Regurgitation Index Before and After Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis 2014
Determining the Timeliness of Key Resuscitative Interventions Among Pediatric Patients Treated for Septic Shock at a Pediatric Tertiary Care Hospital 2014
Effects of Insulin Glargine on Left Ventricular Mass and Function in Patients With Dysglycemia 2014
Effects of School-Based Interventions on Body Mass Index in Children and Adolescents: a Systematic Overview and Meta-analysis 2014
Efficacy of Dabigatran versus Warfarin in Patients With Acute Venous Thromboembolism and Thrombophilia: A Pooled Analysis of RE-COVER™ and RE-COVERTM II 2014
Exome Chip Analysis From the CASPER Registry Highlights Potential Genetic Variant Associated With Unexplained Cardiac Arrest 2014
Favorable Association Between a Mediterranean Dietary Pattern and Cardiovascular Risk Factors in Patients with Stable Coronary Heart Disease in the STABILITY Study 2014
Genotype-Guided Vitamin K Antagonist Dosing Algorithms Improve Time in Therapeutic Range: A Systematic Review and Meta-Analysis 2014
Intravenous Regadenoson with Aminophylline Reversal is Safe and Equivalent to Intracoronary Adenosine Infusion for Fractional Flow Reserve Measurements 2014
Pattern of Atrial Fibrillation and the Risk of Ischemic Stroke - A Systematic Review and Meta-Analysis 2014
Perioperative Mortality and Myocardial Injury Among Patients With Prior High-Risk Cardiac Events Undergoing Non-Cardiac Surgery: A VISON Substudy 2014
Relationships Between 'Mediterranean' and 'Western' Dietary Patterns and Major Cardiovascular Events in Patients With Stable Coronary Heart Disease in the STABILITY Study 2014
Stent Thrombosis and Major Bleeding With Bivalirudin versus Active Control in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials 2014
The New Cardiac Bedside Assessment: Integrating Hand-Held Cardiac Ultrasound into the Evaluation of Cardiac Patients 2014
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis 2013
AMP-activated Protein Kinase is Critical for Regulating Cholesterol Homeostasis in Macrophages 2013
Benefits of Dabigatran versus Warfarin in Hypertensive Patients With Atrial Fibrillation: Results From The Re-ly Trial 2013
Cerebral Co2 Reactivity is Decreased in Children With Post-Bidirectional Glenn Physiology 2013
Does the Degree of Left Ventricular Dysfunction or Symptom Status Influence the Risk of Stroke or Systemic Embolism Among Patients With Atrial Fibrillation and Heart Failure?-Results From the ACTIVE Study 2013
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation - a RE-LY Trial Analysis 2013
Experimental use of a Pediatric Fluid Resuscitation Model: Evaluating Test-retest Reliability and Inter-subject Variability 2013
Impact of Angina on Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease: A Post-Hoc Analysis From the COURAGE Trial 2013
Implantable Cardioverter Defibrillator Events and Mortality in Unexplained Cardiac Arrest Subjects in the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER) 2013
Prehospital Evaluation and Economic Analysis of DIfferent Coronary Syndrome Treatment Strategies (PREDICT)-A Prospective Cohort Study 2013
RE-LY and RELY-ABLE: Long-term Follow-up of Patients With Non-valvular Atrial Fibrillation Receiving Dabigatran Etexilate for Up to 6.7 Years 2013
Rapid Pediatric Fluid Resuscitation: A Randomized Controlled Trail Comparing the Efficiency of Two Provider Endorsed Manual Fluid Resuscitation Techniques 2013
Relationship of PCSK9 With Measures of Vascular Disease and Global Risk in 1574 Individuals Enrolled in the FATE (Fireman And Their Endothelium) Study 2013
Remote Ischemic Preconditioning Does Not Affect Skeletal Muscle Energy Metabolism Measured by 31-Phosphorus Magnetic Resonance Spectroscopy: A Randomized Crossover Trial 2013
Risk of Clinical Outcomes and Baseline Atrial Fibrillation: Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial 2013
Sex-Based Comparison of Angina Severity, Extent of Inducible Ischemia, and Burden of Angiographic Coronary Disease: A Post Hoc Analysis of the COURAGE Trial 2013
Tdag51 Deficiency Protects Against Aortic Vascular Calcification by Attenuating Smooth Muscle Cell Death and Osteoblastic Trans-Differentiation 2013
Why Are patients With Heart Failure and Preserved Ejection Fraction Hospitalized? Data From I-PRESERVE 2013
Ideal Cardiovascular Health Criteria are Inversely Related to Cardiovascular Disease and All-Cause Mortality in a Sample of Canadian Adults 2013
Aspirin for The Prevention of Recurrent Venous Thromboembolism After a First Unprovoked Event: Results of the ASPIRE Randomized Controlled Trial Abstracts 2012
Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years: Results of the Rely-Able Double-Blind Randomized Trial 2012
Reevaluating Epinephrine in Out-of-Hospital Cardiac Arrest: A Systematic Review and Meta-Analysis 2012
Anemia is Associated with an Adverse Outcome in Patients with Atrial Fibrillation: Insights Form the Re-ly Trial 2012
Assessment of Left Atrial Function By 2D-Speckle Tracking Echocardiography in Patients With Severe Organic Mitral Regurgitation: Association With Surgical Indication 2012
Association between Circulating Matrix Gla Protein and Progression of Aortic Stenosis: A Substudy of the ASTRONOMER Trial 2012
Balancing the Benefits and Risks of Two Doses of Dabigatran Compared with Warfarin in Atrial Fibrillation 2012
Brain Abnormalities Causing Surgical Postponement in Single Ventricle Patients Throughout Staged Surgical Reconstruction 2012
Cardiac-Specific Over Expression of Caveolin-3 Protects from Diabetic Cardiomyopathy 2012
Clinical Determinants of Normal Coronary Angiograms in Ontario 2012
Cluster Randomized Controlled Trial to Test The Effect of a Multifaceted Comprehensive Cardiovascular Care Intervention on Clinical Outcomes in Atrial Fibrillation Patients Receiving Dabigatran 2012
Comparison of Dabigatran versus Warfarin in Diabetic Patients with Atrial Fibrillation: Results from the RE-LY Trial 2012
Current Status of Medication Usage for Cardiovascular Disease and Hypertension in China (PURE-China Study) 2012
Dabigatran Versus Warfarin in Very Elderly Patients with Atrial Fibrillation: Results from the RE-LY Trial 2012
Dipeptidyl Peptidase-4 Inhibitors May Reduce the Risk of Major Adverse Cardiovascular Events and All-cause Mortality In Patients With Type 2 Diabetes: Meta-analyses Oof Randomized Controlled Trials 2012
Examining the Role of Endoplasmic Reticulum Stress Induced Glycogen Synthase Kinasea-3 alpha/beta in Accelerated Atherosclerosis 2012
Global Longitudinal Strain And Left Atrial Volume Index Predict Appropriate Implantable Cardioverter Defibrillator Therapy In Hypertrophic Cardiomyopathy Patients 2012
Global Variation in the Incidence of Myocardial Infarction: Increasing Nationwide Trends in Australia from 1993 to 2010 2012
High Prevalence of Cognitive Impairment in Older Heart Failure Patients at Hospital Discharge 2012
Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation - A RELY Substudy 2012
Improved Medical Therapy for Heart Failure: A Population-Based Perspective 2012
Incidence of Pacemaker-Detected Atrial Tachyarrhythmias in Elderly Patients with Hypertension and a History of Stroke or Transient Ischemic Attack 2012
Left Atrial Dysfunction and Cryptogenic Stroke: Novel Insights from Transthoracic Echocardiography 2012
Long-Term Clinical Outcomes of Patients with Type 4a Myocardial Infarction Following Elective PCI for Stable Ischemic Heart Disease (SIHD): Post Hoc Analysis of the COURAGE Trial 2012
Modifying the Seattle Heart Failure Model Improves Survival Prediction in Heart Failure Patients 2012
Obesity and the Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis 2012
One-Year Defibrillator Adjustment is Influenced by Early Device Complications and Poor Mental Health in Primary Prevention Patients 2012
Outcome of Ventricular Tachycardia Ablation in Patients with Nonischemic Dilated Cardiomyopathy: Impact of Noninducibility 2012
P27 Inhibits IkBa-Degradation, Attenuates Inflammation, Improves Cardiac Function and Increases Survival Following LPS 2012
Pericardial Fat is Associated with Left Atrial Structure and Function: Implications for Atrial Fibrillation 2012
Population-Based Evaluation of Appropriate Therapies and Death Among Elderly Implantable Cardioverter Defibrillator (ICD) Recipients: The Ontario ICD Database 2012
Response in Left Ventricular Twist During Dobutamine Stress Echocardiography After ST-segment Elevation Myocardial Infarction Predicts Reverse Remodeling 2012
Self-Management Training Improves Chronic Angina Symptoms but not Psychological Burden 2012
Sr-bi Deficiency is Associated with Dendritic Cell Retention in Arterial Atherosclerotic Plagues and Impaired Atherosclerotic Regression in Apoe-r61 Hypomorphic Mice 2012
MicroRNA-145 Targeted Therapy Reduces Atherosclerosis 2012
Characteristics, treatments and outcomes in young as compared with elderly acute coronary syndrome patients in india (CREATE registry) 2012
Comparison of risk factor reduction and tolerability of a full dose versus low dose of a polypill (polycap) in individuals at high risk of cardiovascular diseases: a phase II, double blind randomized trial 2012
Gender differences in presentation, treatments and outcomes of over 20,000 acute coronary syndromes patients in India: the CREATE registry 2012
INSPIRE: methods and preliminary results of a large stroke registry from India 2012
The Rheumatic Heart Disease Global Registry (REMEDY) study: preliminary report 2012
RISK OF ELECTIVE MAJOR NON-CARDIAC SURGERY AFTER CORONARY STENT INSERTION 2012
Alcohol Effect on Incident Atrial Fibrillation in Individuals with Cardiovascular Disease: Analysis of Data from the ONTARGET and TRANSCEND Studies 2011
Does the 6 Minute Walk Test Provide Useful Prognostic Information in Systolic Heart Failure Patients? 2011
Evolution of Clinical Diagnosis in Patients Presenting with Unexplained Cardiac Arrest 2011
Experimental Lung Fibrosis and Pulmonary Hypertension Induces Cardiomyocyte Apoptosis and Right Ventricular Dysfunction 2011
Extended Anticoagulant Prophylaxis in Initially Hospitalized Medically Ill Patients: Results of the ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) Trial 2011
Global Variation in the Etiology and Management of Atrial Fibrillation: Results from a Global Atrial Fibrillation Registry 2011
Impact of Treatment with Apixaban and Aspirin in Patients with Atrial Fibrillation in Relation to the CHADS2 and CHA2DS2-VASc Scores: the AVERROES Study 2011
Left Ventricular Lead Position and Long-Term Clinical Outcome in the RAFT Trial 2011
Left Ventricular Subepicardial Twist Predicts Left Ventricular Remodeling After Acute Myocardial Infarction 2011
Predictors of Death Within Six Months of Cardiac Resynchronisation Therapy 2011
Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients with Heart Failure and Preserved Ejection Fraction: The I-PRESERVE Trial 2011
The Importance of Right Ventricular Function in Survival Following Cardiac Resynchronisation Therapy 2011
Three-Dimensional Speckle-Tracking Longitudinal-Strain Predicts Improvement of Left Ventricular Function After Acute Myocardial Infarction 2011
What is the Utility of Two Different ELISAs and the 4T's Score in Determining the Probability of Heparin-Induced Thrombocytopenia Following Cardiac Surgery? 2011
Ablation of Pink1 Evokes Spontaneous Early-Onset Cardiac Left Ventricular Hypertrophy and Hypersensitivity to Biomechanical Stress 2010
Cardiac Resynchronization Therapy in Patients With RBBB in the Ontario ICD Registry; Assessment of Contemporary Practice and Outcomes 2010
Characterization of the Learning Curve in Transradial Percutaneous Coronary Interventions 2010
D-dimer is Prognostic for Stroke, Major Bleeding and Death During Anticoagulation of Atrial Fibrillation - a RELY Substudy 2010
Decrease in Matrix Gla Protein Level is Associated with Faster Progression of Aortic Valve Stenosis in a Substudy of ASTRONOMER: Relationship with Age 2010
Derivation and Validation of a Simple Exercise-Based Algorithm for Prediction of Genetic Testing in Relatives of LQTS Probands 2010
Diagnostic Value of Cardiac Troponin T, N-Terminal Pro-Brain Natriuretic Peptide, and High-Sensitivity C-Reactive Protein During Doxorubicin Therapy in Children with Acute Lymphoblastic Leukemia 2010
Effect of Coronary Ischemic Burden on Therapies for Ventricular Tachyarrhythmia (VT) and Death in Patients with an Implantable Cardioverter Defibrillator (ICD) 2010
Evaluating the Effectiveness of Rosuvastatin in Preventing the Progression of Diastolic Dysfunction in Aortic Stenosis: A Substudy of the Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin (ASTRONOMER) Study 2010
Heart Rate is associated with Increased Risk of Major Cardiovascular Events, Cardiovascular and All-Cause Death in Patients with Stable Chronic Cardiovascular Disease - An Analysis of ONTARGET/TRANSCEND 2010
Inactivation of DJ-1/Park7 Promotes Pathologic Cardiac Hypertrophy by Inhibiting Hif-1 alpha and Promoting Myocyte Apoptosis During Biomechanical Stress 2010
Increasing Burden of Environmental Risk Factors for Congenital Heart Disease in the Current Era 2010
Increasing Prevalence of Atrial Fibrillation: Nationwide Hospitalization Trends in Australia Over 15 Years 2010
Late-Gadolinium Enhancement by Cardiac Magnetic Resonance Confers Additive Independent Prognostic Value in New-Presentation Idiopathic Dilated Cardiomyopathy 2010
NT-proBNP is Prognostic for Stroke and Death in Atrial Fibrillation - a RELY Substudy 2010
Pediatric Participation in Research: Lessons Learnt from a Population-based Cardiac Biorepository 2010
Pericardial Adiposity Predicts Atrial Fibrillation Recurrence Following Catheter Ablation 2010
Phosphodiesterase 4D (PDE4D) Enhances Myocardial Contractility by Regulating Sarcoplasmic Reticulum Ca2+ Load 2010
Randomized Trial of Fondaparinux versus Heparin to Prevent Graft Failure After Coronary Artery Bypass Grafting: The Fonda CABG Pilot Study 2010
Sentinel Symptoms in Patients with Unexplained Cardiac Arrest from the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER) 2010
Sodium Bicarbonate Use in Pediatric Shock and Cardiac Arrest: Attitudes of Pediatric Acute Care Physicians 2010
The Effect of Acute Onset Atrial Fibrillation on Left Atrial Thrombogenesis 2010
The Relationship Between Atrial High-Rate Episodes and Stroke: The Asymptomatic Stroke and Atrial Fibrillation Evaluation in Pacemaker Patients (ASSERT) Trial 2010
The Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (RAFT) 2010
The Small Dense LDL phenotype and the Progression of Aortic Stenosis: a substudy of the ASTRONOMER trial 2010
The Systolic to Diastolic Duration Ratio in Children With Dilated Cardiomyopathy Who Need Heart Transplantation or Die 2010
Use of Aspiration Thrombectomy and Practice Patterns During Primary PCI for STEMI - Results of an International Survey 2010
Impact of Societal Influences on Chronic Noncommunicable Diseases in Low, Middle, and High Income Countries: The Prospective Urban Rural Epidemiology (PURE) Study 2010
Potentially Modifiable Risk Factors Associated with Myocardial Infarction in China: The INTERHEART China Study 2010
Predictors of Hypertension Awareness, Treatment, and Control in Rural and Urban Areas of 17 Countries (PURE Study) 2010
Angiogenic Cytokine-conjugated Injectable Hydrogel Stabilized a Cardiac Infarct, Increased Blood Vessel Density and Improved Function 2009
Association Between Longer Blood Conservation and Worse Post-Operative Outcomes in Pediatric Cardiac Surgery 2009
Association Between Thromboembolic Complications and Increased Mortality After Pediatric Cardiac Surgery 2009
BRCA1 is a Novel Regulator of Endothelial Function and Limits Atherosclerosis 2009
Basic Life Support Termination of Resuscitation Guideline Implementation Trial (TORIT) 2009
CT Coronary Angiography for Patient Triage to Invasive Angiography: Comparison of Performance in Patients With and Without Prior Noninvasive Stress Tests 2009
Complications Increase Mortality Risk After De Novo Implantion of a Cardioverter Defibrillator: Initial Findings From the Ontario ICD Database 2009
Determinants of Masked Hypertension in Hypertensive Patients Treated in the Real-Life Observational DioVantageIV Study 2009
Does Lifestyle Modify the Genetic Risk of Obesity? An Association Study of Lifestyle Interactions With FTO Genotype in 21,675 Caucasian Women 2009
Double Blind Randomized Controlled Crossover Studies of the Effects of Remote Preconditioning on the Exercise Performance of Elite Swimmers: Evidence for a Persistent Preconditioned State 2009
Erectile Dysfunction Predicts Cardiovascular Events in High Risk Patients Receiving Telmisartan, Ramipril or Both 2009
High Density Lipoprotein Modulates Glucose Metabolism by Multiple Mechanisms 2009
Impact of the Modified Henry Ford Warfarin Maintenance Dosing Algorithm an Quality of Anticoagulation at a Specialist Anticoagulation Clinic 2009
Influence of Heparin Brand on Immediate Post-Operative Outcomes in Children Undergoing Cardiac Surgery 2009
Metabolomic Profiles Are Associated With Baseline Insulin Resistance and Improvement in Insulin Resistance With Weight Loss in the WLM Trial 2009
Obesity and Its Relationship to Adverse Cardiovascular Outcomes in Older Patients With Heart Failure and Preserved Ejection Fraction in the I-PRESERVE Trial 2009
Physical Limitation Risk Score and Cardiovascular History Predict Death and MI in the COURAGE Trial 2009
Plasma Renin Activity is Associated With Increased Cardiovascular Events and Mortality in the HOPE Study 2009
Prognostic Significance of Markers of Vascular Health: Long-term Results From the Firefighters And Their Endothelium (FATE) Study 2009
Prospective Evaluation of a Comprehensive Genetic Risk Score for Future Cardiovascular Events Among 19,313 Initially Healthy Women: The Women's Genome Health Study 2009
Quality of Life Questionnaire Responsiveness and Lack of Relationship to Functional Capacity: Findings From the Exercise Rehabilitation Trial (EXERT) 2009
The Effect of Ticagrelor in Stable Coronary Artery Disease Patients Nonresponsive to Clopidogrel: The RESPOND Study 2009
The Long Term Mechanical Effects of Permanent Right Ventricular Pacing: The Effects of Pacing Site 2009
The Relation of Quality of Life Score to Outcome in Heart Failure With Preserved Ejection Fraction: Findings From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial (I-PRESERVE) 2009
Hypothermia Therapy After Pediatric Cardiac Arrest 2009
The Effect of Metabolic Syndrome on Global Cardiovascular Risk Reduction in High-Risk Patients with Dyslipidemia on Pharmacotherapy 2009
An Indirect Comparison of the Efficacy and Safety of Factor Xa Inhibitors with Thrombin Inhibitors nn Preventing Various Thromboembolism after Hip or Knee Surgery 2008
Anticoagulation of Patients on Chronic Warfarin Undergoing Arrhythmia Device Surgery: Wide Variability of Perioperative Bridging in Canada 2008
Baseline Physical Limitation is Related to Death and MI in the COURAGE Trial 2008
CASPER: Study Design and Preliminary Results in Probands from the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry 2008
Correlation of Bicuspid Valve Morphology and Pattern of Aortic Root Dilatation: A Substudy of the Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin (ASTRONOMER) Study 2008
Cost of Improvement of Angina-Related Health Status by Health Care System: A Secondary Analysis from the COURAGE Trial 2008
Dexrazoxane Cardioprotection In Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia: Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocol 95-01 Randomized Controlled 2008
Effect of Rosiglitazone on Left Ventricular Systolic and Diastolic Function and on NT-proBNP: Results of the Echocardiographic and Biomarker Substudy of the DREAM Trial 2008
Efficacy and Safety of Clopidogrel in Acute Coronary Syndrome Patients at High Risk of Bleeding: Data from the CURE Trial 2008
High Mortality Rates are Associated with Withdrawal of Beta Blockers and Ace Inhibitors in Chemotherapy-induced Heart Failure 2008
Impact of Alerts on Outcome of the Fidelis Implantable Cardioverter-Defibrillator Lead Advisory: A Report from the Canadian Heart Rhythm Society Device Advisories Committee 2008
Individualized Heparin and Protamine Management Protocol in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery Improves Immediate Post-operative Clinical Outcomes 2008
Inhibition of Inhibitor Kappa B Kinase Beta Augments Endothelial Nitric Oxide Synthase Activity and Nitric Oxide Production in Aortic Endothelial Cells 2008
Late Clinical Outcomes of Diabetic Patients Randomized in the Occluded Artery Trial (OAT) 2008
Morbidity and Mortality of Transthyretin (TTR) Amyloid Cardiomyopathy (ATTR-CM): Transthyretin Amyloidosis Cardiac Study (TRACS) a Prospective Evaluation 2008
No Clear Association Between Candidate Gene Variants and Outcomes In 3239 Patients with Chronic Heart Failure: Results from the CHARM Program 2008
Paradoxical Low Use of Coronary interventions in High-Risk Non-st Segment Acute Coronary Syndromes with Heart Failure. Data from the Oasis-5 Randomized Trial 2008
Prescribing Barriers to Heart Failure Management in Primary Care 2008
Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) - Six Month Outcomes 2008
Correlation between angina and reduced myocardial ischemia: Results from the courage trial nuclear substudy 2008
Effectiveness of optimal medical therapy in the COURAGE trial 2008
Health status and quality of life outcomes in south Asian and European Canadians with coronary artery disease 2008
Nurse practioners improve compliance with venous thromboembolism prophylaxis in hospitalized heart failure patients at St. Joseph's Regional Medical Center 2008
Impact of Change in High-Density Lipoprotein Cholesterol on Cardiovascular Disease Morbidity and Mortality: Systematic Review and Meta-Regression Analysis 2008
Differential improvement in stress myocardial perfusion ischemia following percutaneous coronary intervention as compared with optimal medical therapy alone: Nuclear substudy results from the Clinical Outcomes using Revascularization and Aggressive Drug Evaluation (COURAGE) trial 2007
The perioperative ischemic evaluation (POISE) trial: A randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery 2007
A population-based comparison of the cardiovascular protective effects of hydrochlorothiazide and chlorthalidone 2007
Age-related quality of life and health status outcomes of COURAGE trial patients during long-term follow-up 2007
Anaemia is associated with poor outcome in patients with heart failure and preserved ejection fraction (HF PEF). Findings from the Irbesartan in Heart Failure with Preserved Systolic Function Trial (I-PRESERVE) 2007
Atrial fibrillation is associated with increased risk of fatal and non-fatal cardiovascular events in patients with heart failure and preserved ejection fraction findings from the irbesartan in heart failure with preserved systolic function trial (I-PRESERVE) 2007
Cardiac rehabilitation reduces depression in coronary artery disease patients 2007
Clinical outcomes in women with stable coronary artery disease randomized to optimal medical therapy with or without PCI: Pre-specified subset analysis of the COURAGE trial 2007
Comparison of right ventricular strain and strain rate in patients with Arrhythmogenic right ventricular cardiomyopathy, right ventricular outflow tract tachycardia, and matched controls 2007
Cost effectiveness of adding PCI to optimal medical therapy in patients with stable coronary artery disease: Economic outcomes from the COURAGE trial 2007
Diabetes mellitus is associated with increased risk of fatal and non-fatal cardiovascular events in heart failure patients with preserved ejection fraction - Findings from the Irbesartan in heart failure with preserved systolic function trial 2007
Dietary supplementation with sodium valproate attenuates lesion development in hyperglycemic apolipoprotein E-deficient mice 2007
Elevated in-hospital glucose level, and not known history of diabetes mellitus, predicts 30-day mortality following acute ST-elevation myocardial infarction 2007
Genetic variants associated with acute myocardial infarction risk in five ethnic groups: The INTERHEART genetics study 2007
Glucose levels predict incident cardiovascular events in a large international multiethnic cohort 2007
Household car and television ownership are associated with an increased risk of myocardial infarction: Results from the INTERHEART study 2007
Impact of PCI in patients with recent onset severe angina or stabilized ACS treated with optimal medical therapy: a COURAGE trial high risk subset 2007
Impact of optimal medical therapy with or without PCI on long-term cardiovascular endpoints in patients with stable coronary artery disease: Tertiary outcomes from the COURAGE trial 2007
Obesity metrics and their associations with type 2 diabetes and glucose levels in a large international multi-ethnic cohort 2007
Optimal medical therapy with or without percutaneous coronary intervention for stable coronary artery disease is effective in patients with chronic kidney disease 2007
Quality of life in COURAGE trial patients with diabetes 2007
Relationship between angiographic restenosis and clinical outcomes post-PCI in CAD patients: A pooled analysis of nine trials comparing drug-eluting vs. baremllilletal stents 2007
Renal dysfunction is associated with increased risk of fatal and non-fatal cardiovascular events in patients with heart failure and preserved ejection fraction - Findings from the irbesartan in heart failure with preserved Systolic function trial (I-Preserve) 2007
Strategy of intensive glycemic control with pioglitazone does not significantly reduce in-stent neointimal volume after percutaneous coronary intervention in type 2 diabetic patients 2007
The relative safety and efficacy of clopidogrel in women and men: Meta-analysis of 79,613 patients enrolled in CREDO, CURE, CLARITY-TIMI 28, COMMIT, and CHARISMA 2007
Work and leisure time related physical activity and the risk of myocardial infarction: Results of the INTERHEART study 2007
Quality-of-life and economic outcomes in the Clinical Outcomes Utilizing Percutaneous coronary Revascularization and Aggressive Guideline-driven Drug Evaluation (COURAGE) trial 2007
A family-based intervention to promote healthy lifestyles in an aboriginal community in Canada 2007
Dietary patterns and risk of myocardial infarction in 52 countries: Results of the INTERHEART study 2007
Refinement and validation of a food frequency questionnaire to estimate nutrient intake in South Indians 2007
A psychoeducation trial for people with chronic stable angina 2006
Baseline plasma NT-proBNP concentrations in relation to clinical characteristics: Results from the irbesartan in heart failure with preserved systolic function trial 2006
Cardiac structural changes and diastolic function in heart failure with preserved ejection fraction - Importance of left atrial volume: the iPRESERVE study 2006
Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the heart outcomes prevention evaluation (HOPE) Study 2006
Effect of intravenous iron sucrose on exercise tolerance in anemic and non-anemic patients with symptomatic chronic heart failure and iron deficiency: A randomised, controlled, observer-blinded trial (FERRIC-HF) 2006
Effects of fondaparinux in patients with ST-Segment elevation acute myocardial infarction non-eligible for reperfusion treatment 2006
Endothelial anticoagulant heparan sulfate mediates anti-inflammatory effects of antithrombin in sepsis. 2006
Endothelin-1 antagonism and nitric oxide augmentation prevents CyA induced vasomotor impairment 2006
Fasting plasma glucose is an independent predictor of hospitalization for congestive heart failure in high-risk patients 2006
Fondaparinux versus control (placebo or unfractionated heparin) as an adjunct to thrombolytic therapy in acute myocardial infarction: an OASIS 6 substudy 2006
Guideline adherent antithrombotic treatment is associated with improved cardiovascular outcome compared to undertreatment in real-life atrial fibrillation patients at high risk for stroke 2006
High heritabilities of serum metabolites and differential metabolomic profiles in families burdened with early onset coronary artery disease 2006
Impact of vascular events on mortality in AF patients: Insights from ACTIVE W 2006
Incidence of heparin-induced thrombocytopenia lower than expected patients with acute coronary syndromes. The global registry of acute coronary events 2006
Increase in risk of death in early months following hospitalization for heart failure: Observations from the CHARM program 2006
Lack of interaction between angiotensin receptor blocker and aspirin in patients with heart failure 2006
Long term effects of ultrasound-mediated VEGF165 delivery on microvascular perfusion and endogenous growth factor expression chronic ischemia 2006
Long-term adherence to the ACC/AHA class I post-discharge medications and recommendations using optimal medical therapy in 2,287 patients with established coronary heart disease: Interim data from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial 2006
Major bleeding in patients with acute coronary syndrome undergoing early invasive management can be reduced by fondaparinux, even in the context of trans-radial coronary intervention: Insights from OASIS-5 trial 2006
Neither ramipril nor vitamin E reduces the incidence of atrial fibrillation. Results of the HOPE study. 2006
Noninvasive measures of subclinical atherosclerosis in children, a systematic overview 2006
Should we abandon the paradigm of withholding oral anticoagulation in paroxysmal atrial fibrillation? 2006
Utilization of cardiac biomarkers for the evaluation of chest pain 2006
A high-fiber, low saturated fat diet combined with exercise enhances VO2max and lipid profiles 2006
Long-term effects of a dietary portfolio of cholesterol-lowering foods on blood pressure 2006
Assessment of right ventricular function in adults with repaired tetralogy of fallot using the myocardial performance index 2005
Detection of high-risk atherosclerotic plaques by time-resolved laser induced fluorescence spectroscopy 2005
Diastolic dysfunction in heart failure with preserved systolic - Function need for objective evidence. Results from the CHARM echocardiographic substudy - CHARMES 2005
Effect of recombinant human growth hormone on functional capacity and quality of life in heart failure patients: Results from the growth hormone in heart failure trial (GIFT) 2005
Efficacy and safety at 3 years of the sirolimus-eluting stent to treat de novo long coronary artery lesions in the Canadian multicenter, randomized, double-blind trial C-SIRIUS 2005
Global myocardial diastolic function does not improve with the transplantation of autologous bone marrow-derived stem cells in patients with acute myocardial infarction 2005
Hypothermia therapy after pediatric cardio-respiratory arrest 2005
Identification and functional analysis of CITED2 mutations in patients with congenital heart defects 2005
Impact of patient and target vessel characteristics on arterial and venous bypass graft patency: Insight from a randomized trial 2005
Implantable cardioverter-defibrillators in ventricular assist device-supported heart failure patients bridged to cardiac transplant 2005
Inhibition of SMC proliferation and in-stent intimal hyperplasia by overexpression of p15, an INK4 cyclin-dependent kinase inhibitor 2005
Left ventricular dysfunction and mortality in patients with Eisenmenger syndrome 2005
Patients with atrial fibrillation induced tachycardiomyopathy are at high risk for stroke 2005
Prevalence of intraplaque hemorrhage in vasculopathic patients with asymptomatic carotid stenosis 2005
Reduced right ventricular deformation in children with severe pulmonary regurgitation after tetralogy of Fallot correction is associated with reduced exercise capacity 2005
Regional myocardial systolic function measured with myocardial velocity imaging improves with the transplantation of autologous bone marrow-derived stem cells in patients with large acute myocardial infarction 2005
Relationship of telomere length to endothelial function in healthy middle-aged men 2005
The acute effect of anthracyclines on cardiac function assessed with strain rate imaging 2005
The effects of Ramipril on C-reactive protein and endothelial function in healthy volunteers at low to intermediate risk: A randomized controlled study 2005
Current prevalence and control of dyslipidemia in the primary care setting 2005
High correlation between local clinical laboratory and lipid research core laboratory lipid and lipoprotein measurements in a large randomized clinical trial 2005
Prescription choices for treatment and control of dyslipidemia in primary care 2005
Trends in community mortality attributed to heart failure 2005
Use of pharmacologic and nonpharmacologic management approaches in patients hospitalized with heart failure: A population-based perspective 2005
Long-term trends (1990 to 2003) and outcomes associated with the use of angiotensin-converting enzyme inhibitors in patients hospitalized for acute myocardial infarction: A community-wide perspective 2005
Need for substantial revision of criteria for overweight and obese among South Asians and chinese compared to Europeans to predict the risk of metabolic abnormalities 2005
Trends in community mortality attributed to heart failure 2005
Impact of glucose-insulin-potassium on mortality and morbidity in over 20,000 patients with acute myocardial infarction: The CREATE-ECLA international trial 2005
Rurality influences on women after myocardial infarction 2005
Accuracy of noninvasive monitoring of coronary flow velocity reserve with transthoracic echo-Doppler in detecting coronary restenosis after successful coronary angioplasty: A multicenter study 2004
Adherence, even to placebo, is strongly and independently related to outcome in patients with chronic heart failure: Results from the CHARM program 2004
An impaired myocardial deformation can be detected late after low anthracycline dose using strain and strain rate imaging 2004
Baseline high-sensitivity C-reactive protein offers prognostic value in addition to contemporary risk stratification in non-ST-segment elevation acute coronary syndrome: Results from the CURE inflammatory marker substudy 2004
Competitive flow compromises Radial Artery Graft Patency: Analysis of angiographic data from a randomized controlled clinical trial 2004
Do women and men differ at time of referral for PCI? Experience from the courage clinical trial 2004
Early enalapril therapy reduced cardiovascular morbidity and mortality in patients with left ventricular systolic dysfunction: Results at 15 years in SOLVD 2004
Echocardiographic assessment of end-diastolic wall thickness can be used as a marker of reperfusion in transmural and partial-thickness infarcts 2004
Effect of exercise training on myocardial blood flow in patients with stable coronary artery disease 2004
Folic acid improves endothelial dysfunction in type 2 diabetes, an effect independent of homocysteine lowering 2004
Impact of candesartan in preventing myocardial infarction: Results of the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) programme 2004
Intracardiac thrombus in adults with Fontan operation: Treatment and clinical outcome 2004
One-year cost analysis of off-pump CABG versus on-pump CABG: The Canadian off-pump registry 2004
Predicting mortality and morbidity in chronic heart failure independent of left ventricular systolic function: Results from the CHARM program 2004
Prehospital delay, receipt of Reperfusion therapy, and hospital outcomes. Observations from the Global Registry of acute Coronary Events 2004
Prehospital delay, timing of hospital presentation and receipt of reperfusion therapy, and hospital outcomes 2004
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis 2004
Social-environmental and behavioral factors independently contribute to 10-year absolute risk for coronary disease on the Framingham index 2004
Telomerase triggers angiogenesis and is required for VEGF responsiveness in hind-limb ischemia 2004
Unrecognized cognitive impairment is common in heart failure outpatients 2004
Multidisciplinary heart failure care: A survey reviewing continuation of strategies proven in randomized clinical trials 2004
Superior immediate and longterm outcomes in ACS patients are achieved by initiating statin therapy without in-hospital cholesterol measurement 2004
Changes in obesity status are not related to changes in physical activity: A five-year study of youth. 2004
Longitudinal development of BMI and blood pressure in childhood and adolescence. 2004
A combination of cholesterol-lowering dietary components (dietary portfolio) versus statin on serum lipids 2003
Early treatment with enalapril in patients with left ventricular systolic dysfunction protected against death and serious cardiovascular morbid events at 12 years in SOLVD 2003
Impact of the results of a women's health initiative trial on hormone replacement therapy use 2003
Interleukin 18 as a predictor of myocardial infarction in the Heart Outcomes Prevention Evaluation (HOPE) study 2003
Lipid-lowering with atorvastatin in children and adolescents with familial hypercholesterolemia: Impact on endothelial dysfunction 2003
Long-term cost effectiveness of platelet inhibition with clopidogrel in patients presenting with acute coronary syndromes: Results from the CURE trial 2003
Long-term cost effectiveness of platelet inhibition with clopidogrel in patients undergoing PCI after presenting with an acute coronary syndrome: Results from PCI-CURE 2003
Myocardial cell transfer analysis using In Vivo Imaging technique 2003
N-acetylcysteine does not potentiate hypotension caused by nitroglycerin during percutaneous coronary intervention 2003
N-acetylcysteine does not prevent long-term clinical events despite reducing periprocedural contrast-associated nephropathy 2003
Novel antithrombotic drug reduces arterial Doppler high intensity transient signals during and after hypothermic cardiopulmonary bypass in pigs 2003
Obesity predicts atherogenic metabolic abnormalities and atherosclerosis 2003
Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart 2003
Plasma metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in heart failure patients 2003
Relationship between CRP and endothelial function in 1097 asymptomatic middle-age men enrolled in the FATE study 2003
The Canadian off-pump CABG registry: Interim analysis of early and long-term clinical outcomes 2003
Troponin status is more useful than creatine kinase in predicting one-year mortality in acute coronary syndrome patients 2003
Viral pathogen scores and subsequent cardiac events in the HOPE study 2003
Weight-loss in obese insulin-resistant mice induces changes in the adipose tissue gene expression profile that are associated with reversal of hypertriglyceridemia, increase of insulin-sensitivity and glucose tolerance, prevention of atherosclerosis, and improvement of cardiac function 2003
A behavioral protocol to enhance vagal modulation of heart rate: The Heart Rate Variability Biofeedback Trial 2002
Aspirin dose and bleeding events in the CURE study 2002
Benefit of Clopidogrel in patients with acute coronary syndromes without ST-segment elevation (ACS) in various risk groups 2002
Beta receptor selectivity of carvedilol versus metoprolol succinate: A dose ranging study 2002
Correlation between noninvasive measures of anatomic extent of subclinical atherosclerosis and endothelial function 2002
Does early withdrawl of statin therapy in patients with acute coronary syndromes increase hospital morbidity and mortality? 2002
Effect of direct thrombin inhibitors on reducing death and myocardial infarction in acute coronary syndromes is greater in patients undergoing percutaneous coronary intervention 2002
Effect of the v-protectant/antioxidant AGI-1067 on the QT interval in the Canadian antioxidant restenosis trial (CART-1) 2002
Impact of cigarette smoking in patients at high risk of cardiovascular disease. The heart outcomes prevention evaluation (HOPE) Study 2002
Infarct size is smaller in women versus men with acute myocardial infarction 2002
Initiating a tobacco cessation program during hospitalization for acute coronary events improves long term cessation rates 2002
Long-term prognosis of patients with heart failure and reduced ejection fractions - 12-year follow-up of the studies of left ventricular dysfunction 2002
Molecular regulation of myogenic stem cells lacking the forkhead/winged helix transcription factor, Foxk1 2002
Predicting prognosis in 2,380 women referred for cardiac rehabilitation 2002
Prospective randomized study of conventional vs. irrigated radiofrequency ablation of atrial fibrillation: A pilot study 2002
Racial differences in outcome and treatment effect in heart failure (HF) in Digitalis Investigation Group (DIG) trial 2002
Rapid emergence of benefit with clopidogrel followed by incremental reduction in major cardiovascular events with long term therapy after acute coronary syndrome: Insights from the CURE trial 2002
Selective pharmacological inhibition and targeted knockdown of K+ inward rectifier channels IK1 (Kir2.1) abolish protection by ischemic preconditioning in rabbit ventricular myocytes 2002
The cost-effectiveness of the use of Clopidogrel in acute coronary syndromes based upon the CURE study 2002
The metabolic syndrome in children and adolescents 2002
Cost analysis of off-pump CABG versus on-pump CABG: Canadian Off-Pump Registry study 2002
Angiotensin receptor blockers in heart failure: Meta-analysis of randomized controlled trials 2001
Cardiovascular events still drive mortality in patients with asymptomatic left ventricular dysfunction treated with ACE-inhibitors 2001
Cardiovascular morbid events in left ventricular dysfunction treated by ACE-inhibitors: Ten-years follow-up post SOLVD close out 2001
Cellular and molecular adaptations are insufficient for the maintenance of cardiac function in myoglobin deficient mice 2001
Decreasing incidence and improved short term prognosis of complete heart block complicating acute myocardial infarction over two decades: The Worcester heart attack study 2001
Does greater platelet inhibition explain abciximab's superiority in the TARGET trial? A randomized clinical comparison. 2001
Effects of AGI-1067 on restenosis rates in patients undergoing percutaneous coronary intervention with stent placement in the Canadian antioxidant restenosis trial (CART-1) 2001
Fractionated and unfractionated heparin exert differing affects on endothelial cell tissue factor pathway inhibitor (TFPI) release 2001
Identification of specific calcium pools involved in NFAT translocation in myocytes 2001
Impact of abdominal obesity on the occurrence of diabetes in subjects with ischemic cardiovascular disease 2001
Infections as risk markers for subsequent cardiovascular events in the HOPE trial 2001
Inflammatory markers and risk of subsequent cardiovascular events in the HOPE trial 2001
Metoprolol prophylaxis against post-operative atrial fibrillation increases length of hospital stay in patients not on pre-operative beta-blockers: The beta-blocker length of stay (BLOS) trial 2001
Myogenic STEM cells display impaired cell cycle progression in the absence of the winged helix transcription factor, FoxK1 (MNF) 2001
Natriuretic peptides in chronic stable heart failure patients treated with omapatrilat, a vasopeptidase inhibitor: The IMPRESS neurohormone substudy. 2001
Neopterin: Novel marker of endothelial dysfunction in humans 2001
Predictors of stroke in patients paced for sick sinus syndrome 2001
Prevention of atrial fibrillation after cardiac surgery: A meta-analysis 2001
Results of the Canadian antioxidant restenosis trial (CART-1) 2001
The effect of clinical risk stratification on the cost-effectiveness of the implantable cardioverter-defibrillator: The Canadian implantable defibrillator study 2001
Usefulness of early noninvasive coronary flow reserve assessment by contrast enhanced transthoracic Doppler in predicting restenosis after successful coronary angioplasty 2001
Variations in practice patterns and clinical outcomes in 12,512 patients with non-ST elevation acute coronary syndromes (ACS) recruited in 13 countries and 5 continents. 2001
What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial 2001
Current practices and attitudes toward cholesterol management in patients with recent acute myocardial infarction: A survey of community physicians 2001
Temporal trends (1986-1997) in cholesterol assessment and management practices in patients hospitalized with acute myocardial infarction: A population-based perspective 2001
A quantitative method for defining scar with F-18-FDG PET predicts the degree of recovery of LV function post-revascularization 2000
Cardiopulmonary exercise performance in adult survivors with the Mustard procedure 2000
Chloride channels are end-effectors of adenosine A(1) receptor and protein kinase C preconditioning in rabbit ventricular myocytes 2000
Coronary flow reserve in the infarct related artery correlates with post infarction myocardial viability and functional recovery 2000
Does larger infarct size explain the higher mortality in the elderly with acute myocardial infarction? 2000
Effect of inhibition of vessel wall elastase by local expression of elafin on neointima formation in response to balloon injury 2000
Effects of ramipril on the incidence of myocardial infarction in high risk patients: The HOPE Study 2000
Excess body weight does not adversely influence either bioavailability or anticoagulant activity of enoxaparin administered subcutaneously in acute coronary syndromes 2000
Increased cyclooxygenase-2 (COX-2) expression in acute myocardial infarction: Therapeutic target of a selective COX-2 inhibitor 2000
Inhibition of cyclooxygenase-2 prevents myocardial dysfunction and improves cardiomyocyte survival in ischemic heart failure 2000
Metabolic and hematological effects of ramipril in the HOPE trial 2000
Multivessel percutaneous coronary revascularization early after acute myocardial infarction 2000
Predictive value of natriuretic peptides and endothelin-1 for LV remodeling in response to candesartan and enalapril: The RESOLVD neurohumoral ancillary study 2000
Prognostic value of serum troponin T and troponin I in heart failure 2000
Renal insufficiency as a predictor of cardiovascular outcomes and impact of ramipril: The HOPE study 2000
Skin cholesterol: A new method to predict angiographic disease 2000
Temporary discontinuation of oral anticoagulants: Role of low molecular weight heparin (dalteparin) 2000
The long-term predictive value of cardiopulmonary exercise testing (CPXT) in the cardiac rehabilitation setting 2000
The multiple metabolic syndrome in young adolescents 2000
Minimal and best linear combination of oxidative stress and antioxidants biomarkers to discriminate cardiovascular disease 2000
Postmenopausal estrogen use and insulin sensitivity: The third national health and nutrition examination survey, 1988-1994 2000
Vascular disease - HOPE (Heart Outcomes Prevention Evaluation) 1999
Are intracoronary stents and abciximab associated with better outcomes following rotational atherectomy? 1999
Beta blocker therapy improves cardiac efficiency in patients with left ventricle dysfunction 1999
Congestive heart failure complicating acute myocardial infarction: NRMI-2 registry 1999
Coronary stent placement is associated with improved outcomes in diabetics with acute myocardial infarction treated with primary percutaneous coronary intervention 1999
Decision analysis model of primary stenting versus angioplasty and provisional stenting in the treatment of stable coronary artery disease: A southwestern Ontario perspective 1999
Does angioplasty prolong survival in patients with multivessel disease? Results from the bypass angioplasty revascularization investigation (BARI) 1999
Effect of pacemaker dependency on the benefit of physiologic over ventricular pacing 1999
Effects of digoxin on worsening of symptoms of congestive heart failure in the digitalis investigation group (DIG) trial 1999
Fibrinogen exerts varying effects on GPIIb/IIIa receptor-directed platelet inhibition invitro 1999
Impact of a history of heart failure on outcome in patients with acute coronary syndromes: An analysis from the OASIS registry 1999
Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS registry 1999
Increased morbidity and mortality in diabetic patients with acute myocardial infarction is not explained by larger infarct size or poorer left ventricular systolic dysfunction: insights from the CORE study. 1999
Invasive versus conservative management of unstable angina and non-Q-wave infarction: A meta-analysis 1999
LDL-containing immune complexes induce macrophage matrix metalloproteinase-1 expression via activation of a Fc gamma receptor I-linked mitogen-activated protein kinase pathway 1999
Lack of correlation between structural and functional abnormalities of the coronary circulation in early atherosclerosis 1999
Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction 1999
Metoprolol in chronic heart failure: Natriuretic peptides involved in mechanism of action? 1999
Primary percutaneous coronary intervention in acute myocardial infarction: Evidence for decreasing mortality 1999
Prophylaxis of venous thromboembolism in acute medical patients with enoxaparin: An international, randomized double-blind, placebo-controlled trial 1999
Results of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE) 1999
Risk factors of hospitalization for heart failure in the Canadian Trial of Physiologic Pacing 1999
Synergistic effects of GPIIb/IIIa antagonists and heparin on platelet-dependent procoagulant activity and thrombin generation 1999
The benefit of enoxaparin in Q-Wave myocardial infarction: A sub-study of the TIMI 11B and ESSENCE meta-analysis 1999
The effect of intracoronary stents an percutaneous revascularization outcomes in the presence of left ventricular dysfunction 1999
The influence of creatinine clearance on maximal and steady state factor Xa inhibitory capacity following low molecular weight heparin administration 1999
Treatment benefit of enoxaparin in unstable Angina/non-Q wave myocardial infarction is maintained at one year followup in TIMI 11B 1999
Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in unstable angina (USA) and Non-Q-Wave myocardial infarction (NQMI): A mete-analysis 1999
Weight loss in chronic heart failure (CHF) and the impact of treatment with ACE inhibitors - Results from the SOLVD treatment trial 1999
Relationship between occasional fill consumption and acute myocardial infarction in South Asian Indians 1999
Cardiovascular risk factor management in the very old: A survey of 300 Canadian physicians. 1998
Current weight-adjusted heparin dosing strategies provoke excessive systemic anticoagulation 1998
Decision analysis model of primary angioplasty versus thrombolysis in the treatment of myocardial infarction: A southwestern Ontario perspective 1998
Does the patient with severe LV dysfunction have impaired cardiac efficiency? 1998
Effect of age on mortality, hospitalizations, and response to digoxin in patients with heart failure: The DIG study 1998
Effects of long term oral anticoagulation therapy in addition to aspirin in patients with acute coronary syndromes without ST elevation: a substudy of the OASIS-2 trial. 1998
Effects of recombinant hirudin compared to heparin in patients with acute ischemia without ST elevation - Results of the OASIS-2 trial. 1998
Enoxaparin for the acute and chronic management of unstable angina non-Q wave myocardial infarction: Results of TIMI 11B 1998
Exercise activates the thrombotic/fibrinolytic system in patients with coronary artery disease 1998
In hospital & 6-month outcomes of planned vs rescue abciximab(Reorpo) during PTCA. 1998
Increased winter mortality from myocardial infarction and stroke: The effect of age. 1998
Is there gender bias in the referral of patients with myocardial ischemia to coronary angiography? 1998
Randomized comparison of moderate (INR 3.0-3.5) with low intensity (INR 2.0-3.5) anticoagulant therapy in patients with prosthetic heart valves treated with aspirin (100 mg/day). 1998
Risk factors for stroke in patients with unstable angina (UA) or suspected myocardial infarction (MI) without ST segment elevation. Results from the OASIS registry. 1998
Single versus double versus triple therapy to block neurohormonal effects on ventricular remodeling 1998
The effect of ejection fraction on the relative benefit of the implantable defibrillator in the Canadian implantable defibrillator study 1998
V20, a glycoprotein IIb/IIIa-independent inhibitor of platelet-dependent clotting reactions, inhibits both arterial and venous-type thrombosis in primates 1998
A school-based intervention can reduce body fat and blood pressure in young adolescents. 1998
Correlates of markers of oxidative status in the general population 1998
A randomized trial of weight-adjusted heparin dosing and bedside coagulation monitoring in patients with thrombotic disorders 1997
Albuminuria is highly prevalent and predicts cardiovascular events in high risk diabetic and nondiabetic patients 1997
Central nervous system mediated neurocardiac effects of visceral sensory afferents in humans 1997
Clinical evaluation of the pharmacology, and safety of Vasoflux(TM), a novel antithrombotic 1997
Effects of Candesartan, enalapril or their combination on exercise capacity, ventricular function, clinical deterioration and quality of life in heart failure: Randomized evaluation of strategies for left ventricular dysfunction (resolved) 1997
Effects of new blood pressure standards on prevalence of hypertension in youth 1997
Factors affecting the use of invasive facilities in patients with unstable angina or suspected non-q wave infarction 1997
Incomplete revascularization via PTCA vs CABG: The bypass angioplasty revascularization investigation (BARI) 1997
Is there a difference in platelet surface glycoprotein IIb/IIIa receptor response to pharmacologic inhibition among men and women with myocardial infarction? 1997
Is there a gender bias in the cardiovascular drug treatment of high-risk women? 1997
Left ventricular hypertrophy is a potent independent risk factor for adverse cardiovascular outcomes 1997
Long-term anticoagulation in patients with unstable angina: The OASIS pilot study 1997
Men and women have equivalent thrombin-mediated prothrombotic capacity in the setting of acute myocardial infarction. 1997
Meta-analysis of individual patient data from trials of long-term ACE-inhibitor treatment after acute myocardial infarction (SAVE, AIRE, and TRACE studies) 1997
Platelet inhibition with the glycoprotein IIb/IIIa receptor antagonist Lamifiban in high risk patient subsets: Studies to determine the correlation between platelet-mediated prothrombotic activity and clinical risk 1997
Preconditioning of counterconditioning in patients with preinfarction angina? Insights offered from GUSTO-1 Trial 1997
Quality of life in patients with bioprostheses and mechanical prostheses evaluation of cohorts of patients 51-65 years at implantation 1997
Risk of death, myocardial infarction and strokes in relationship to an invasive or conservative strategy in unstable angina or non-Qwave myocardial infarction 1997
Time dependant changes in myocardial blood flow and sympathetic reinnervation post acute myocardial infarction 1997
Amiodarone side effects and laboratory abnormalities - Reliable rates from a large double-blind trial. 1996
Continuous relationship of glucose with cardiovascular events in non diabetic subjects: A meta regression analysis of 18 studies in 88,000 individuals. 1996
Diabetes is an independent risk factor for increased left ventricular mass 1996
Double blind comparison of aspirin with warfarin following bioprosthetic heart valve replacement. 1996
Effect of baseline characteristics on outcomes in an international prospective registry of acute myocardial ischemia without ST elevation 1996
Hirudin (HBW-023) suppresses markers of coagulation more effectively than heparin 1996
Is systemic to pulmonary shunt a safe procedure for cyanotic adults 1996
LV function and infarct size predict six-month mortality post MI treated by thrombolysis 1996
Of rate and rhythm control in 3903 patients with atrial fibrillation 1996
Patterns of autonomic dysregulation in congestive heart failure: Relationship with LV function and neurohumoral activation 1996
Primary end point analysis from the ESSENCE trial: Enoxaparin vs unfractionated heparin in unstable angina and non-Q wave infarction. 1996
Which heart failure patients benefit the most from long term digoxin therapy? 1996
Which patients surviving acute myocardial infarction are most likely to benefit from amiodarone? 1996
Which patients surviving acute myocardial infarction are most likely to benefit from amiodarone? 1996
Why do patients with right ventricular infarction have a poor prognosis? 1996
3-DIMENSIONAL ECHOCARDIOGRAPHY OF VENTRICULAR SEPTAL-DEFECTS BEFORE AND AFTER TRANSCATHETER CLOSURE WITH A MODIFIED RASHKIND UMBRELLA 1995
CURRENT MORTALITY-RATE OF DIAGNOSTIC CARDIAC-CATHETERIZATION - THE IMPORTANCE OF LEFT MAIN CORONARY-ARTERY DISEASE AND CATHETER-INDUCED TRAUMA 1995
DEMONSTRATION OF THE BOLD EFFECT IN HUMAN MYOCARDIUM 1995
EFFECTS OF ORAL ANTICOAGULANTS ON MORTALITY, REINFARCTION AND STROKE AFTER MYOCARDIAL-INFARCTION 1995
EVALUATION OF RHEOTHRX(R), A NOVEL HEMORHEOLOGIC AGENT, IN ACUTE MYOCARDIAL-INFARCTION 1995
EVIDENCE FOR REBOUND ACTIVATION OF THE COAGULATION SYSTEM AFTER CESSATION OF INTRAVENOUS ANTICOAGULANT-THERAPY FOR ACUTE MYOCARDIAL-ISCHEMIA 1995
HIGH-RESOLUTION MAGNETIC-RESONANCE-IMAGING OF CORONARY-ARTERIES 1995
A NOVEL INHIBITOR OF THROMBIN CONTAINING MULTIPLE RECOGNITION SEQUENCES LINKED BY A ALPHA-KETO AMIDE TRANSITION-STATE MIMETIC 1994
BIOCHEMICAL DIFFERENTIATION BETWEEN DIFFERENT CLASSES OF UNSTABLE ANGINA 1994
COMPARATIVE EFFECTS OF LOSARTAN AND ENALAPRIL ON EXERCISE CAPACITY AND CLINICAL STATUS IN PATIENTS WITH HEART-FAILURE 1994
FAMILIAL RESEMBLANCE OF THE LIPID PROFILE - A LONGITUDINAL TWIN-FAMILY STUDY 1994
HEART-RATE-VARIABILITY AND DEPRESSION - A LINKAGE 1994
IMPORTANCE OF INSULIN-RESISTANCE AND BODY-FAT DISTRIBUTION IN ADDITION TO CONVENTIONAL RISK-FACTORS FOR THE DEVELOPMENT OF MYOCARDIAL-INFARCTION IN ASIAN INDIANS 1994
INHOMOGENEOUS RETROGRADE CARDIOPLEGIA 1994
MONOSTRUT BJORK-SHILEY (SORIN) VALVE - SUCCESSFUL EVOLUTION - THE WELDED OUTLET STRUT GENERATION 1994
SCHOOL-BASED PROGRAMS TO IMPROVE CV HEALTH - EFFECTS IN RURAL AND URBAN AREAS 1994
STEROID INHIBITION OF CYTOKINE-MEDIATED VASODILATION AFTER WARM HEART-SURGERY 1994
STIMULATION OF TPA-MEDIATED PLASMINOGEN ACTIVATION BY PHYSIOLOGICAL FIBRIN DEGRADATION PRODUCTS 1994
THE RANDOMIZED CONTROLLED CLINICAL-TRIALS OF PTCA IN ACUTE MYOCARDIAL-INFARCTION - A SYSTEMATIC OVERVIEW (METAANALYSIS 1994
A COST-EFFECTIVENESS ANALYSIS OF LOW-MOLECULAR-WEIGHT HEPARIN COMPARED WITH CONTINUOUS INTRAVENOUS HEPARIN IN THE TREATMENT OF PROXIMAL-VEIN THROMBOSIS 1993
A DEFINITIVE NONINVASIVE STRATEGY FOR THE MANAGEMENT OF PATIENTS WITH SUSPECTED PULMONARY-EMBOLISM 1993
BASE-LINE QUALITY-OF-LIFE PREDICTS MORBIDITY AND MORTALITY IN 5210 PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION (SOLVD PREVENTION AND TREATMENT TRIALS) 1993
COMPARISON OF MORTALITY FROM ACUTE MYOCARDIAL-INFARCTION BETWEEN 1980, 1987, AND 1992 IN A GEOGRAPHICALLY-DEFINED STABLE-POPULATION 1993
DIABETES PREDICTS MORBIDITY AND MORTALITY IN THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION TRIALS 1993
ECHOCARDIOGRAPHIC PREDICTORS OF ONE-YEAR CLINICAL OUTCOME IN THE STUDY OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD) TRIAL AND REGISTRY - AN ANALYSIS OF 1172 PATIENTS 1993
EFFECTS OF LONG-TERM ENALAPRIL ON ADRENERGIC ACTIVITY AND SENSITIVITY DURING EXERCISE IN PATIENTS WITH LEFT-VENTRICULAR SYSTOLIC DYSFUNCTION 1993
EFFECTS OF SCHOOL-BASED INTERVENTIONS FOR CHILDREN WITH CARDIOVASCULAR RISKS 1993
ESTIMATION OF RESISTANCE TO STREPTOKINASE - A PRELIMINARY-REPORT OF A RAPID BEDSIDE TEST 1993
IN ASYMPTOMATIC PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION, NOT ON ENALAPRIL, THE PROGRESSION OF VENTRICULAR DILATION CORRELATES WITH PLASMA NOREPINEPHRINE LEVELS 1993
LOW-MOLECULAR-WEIGHT HEPARINS SHOW PROLONGED ANTI-IIA PLASMA HALF-LIFE 1993
SILENT ISCHEMIA IN SURVIVORS OF ACUTE MYOCARDIAL-INFARCTION (SISAMI STUDY) - SUPERIOR PROGNOSTIC VALUE OF HOLTER MONITORING EARLY POST MYOCARDIAL-INFARCTION 1993
THE LIMITATIONS OF HEPARIN AND POTENTIAL ADVANTAGES OF NEW ANTICOAGULANTS 1993
THE LOW PROBABILITY LUNG-SCAN - A NEED FOR CHANGE IN NOMENCLATURE 1993
A PHASE-II STUDY OF HIRULOG IN THE PREVENTION OF VENOUS THROMBOSIS AFTER MAJOR HIP OR KNEE SURGERY 1992
ALPHA-2-ANTIPLASMIN INHIBITS TISSUE PLASMINOGEN-ACTIVATOR INDUCED FIBRINOGENOLYSIS AND BLEEDING WITHOUT AFFECTING THROMBOLYSIS 1992
APTTS AFTER THROMBOLYSIS AND STANDARD INTRAVENOUS HEPARIN ARE OFTEN LOW AND CORRELATE WITH BODY-WEIGHT, AGE AND SEX - EXPERIENCE FROM THE GUSTO TRIAL 1992
BENEFITS OF PHYSICAL-TRAINING IN PATIENTS WITH HEART-FAILURE 1992
DIFFERENCES IN PRESENTATION, MORBIDITY AND MORTALITY BETWEEN MEN AND WOMEN WITH LEFT-VENTRICULAR DYSFUNCTION 1992
EFFECTS OF A LARGE GROUP VERSUS A SMALL-GROUP, INDIVIDUALIZED PROGRAM FOR ELEMENTARY-SCHOOL-CHILDREN WITH MULTIPLE CARDIOVASCULAR-DISEASE RISK-FACTORS - THE CARDIOVASCULAR HEALTH IN CHILDREN STUDY 1992
EFFECTS OF A SCHOOL-BASED INTERVENTION ON CARDIOVASCULAR-DISEASE RISK-FACTORS IN ELEMENTARY-SCHOOL-CHILDREN - THE CARDIOVASCULAR HEALTH IN CHILDREN STUDY 1992
HEPARIN BINDING-PROTEINS - POSSIBLE CAUSE OF HEPARIN REBOUND FOLLOWING CARDIOPULMONARY BYPASS 1992
HEPARIN IN THE PRESENCE OR ABSENCE OF ANTIPLATELET THERAPY - AN OVERVIEW OF RANDOMIZED TRIALS IN ACUTE MYOCARDIAL-INFARCTION 1992
LONG-TERM EFFECTS OF ENALAPRIL ON LEFT-VENTRICULAR DIASTOLIC PROPERTIES - EVIDENCE FOR REVERSED REMODELING 1992
LONG-TERM EFFECTS OF ENALAPRIL ON LEFT-VENTRICULAR DILATATION IN ASYMPTOMATIC PATIENTS WITH REDUCED EJECTION FRACTION - COMPARISON WITH SYMPTOMATIC PATIENTS 1992
LUMEN RENARROWING FOLLOWING PTCA - RELATION TO LUMEN GAIN AT PTCA 1992
MECHANISM BY WHICH CLOT-BOUND THROMBIN IS PROTECTED FROM INACTIVATION BY FLUID-PHASE INHIBITORS 1992
OVERVIEW OF RANDOMIZED TRIALS OF LOW-DOSE AMIODARONE ON MORTALITY IN CARDIAC PATIENTS 1992
PROGNOSTIC IMPORTANCE OF INFARCTION AND UNSTABLE ANGINA IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION 1992
REDUCED BINDING OF LOW-MOLECULAR-WEIGHT HEPARINS TO PLASMA-PROTEINS 1992
REGIONAL DISTRIBUTION AND WASHOUT OF 6-[F-18] FLUORODOPAMINE AS A MEASURE OF CARDIAC SYMPATHETIC ACTIVITY IN MAN 1992
THE EFFECT OF PLASMA-PROTEINS ON THE ANTI-IIA AND ANTI-XA ACTIVITIES OF STANDARD HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN 1992
RACIAL AND RURAL URBAN DIFFERENCE IN CARDIOVASCULAR RISK-FACTORS IN NORTH-CAROLINA CHILDREN 1992
REPORTED ACTIVITY LEVELS OF CHILDREN DO NOT REFLECT AEROBIC CAPACITY 1992
DIFFERENCES BETWEEN MEN AND WOMEN WITH LEFT-VENTRICULAR DYSFUNCTION 1991
LOW PLASMA-CHOLESTEROL AND MORTALITY - THE LIPID RESEARCH CLINICS FOLLOW-UP-STUDY 1991
A HEPARIN NOMOGRAM FOR THE MANAGEMENT OF HEPARIN-THERAPY IN VENOUS THROMBOSIS 1990
A PRECISE PROTOCOL FOR INTRAVENOUS HEPARIN-THERAPY FOR VENOUS THROMBOSIS 1990
CANADIAN AMIODARONE MYOCARDIAL-INFARCTION ARRHYTHMIA TRIAL (CAMIAT) PILOT RESULTS 1990
CIRCADIAN-RHYTHMS IN ACUTE MYOCARDIAL-INFARCTION (AMI) 1990
EFFECT OF ANTIARRHYTHMIC DRUG-THERAPY ON MORTALITY FOLLOWING MYOCARDIAL-INFARCTION 1990
EFFECT OF INTRAVENOUS MAGNESIUM ON MORTALITY IN MYOCARDIAL-INFARCTION 1990
EFFECT OF OXYGEN FREE-RADICALS AND SCAVENGERS ON MYOCARDIAL COLLAGEN DURING ISCHEMIA-REPERFUSION 1990
INOTROPIC AGENTS INCREASE MORTALITY IN PATIENTS WITH CONGESTIVE-HEART-FAILURE 1990
PLASMA-LIPIDS AS PREDICTORS OF CHD IN OLDER MEN AND WOMEN - THE LRC FOLLOW-UP-STUDY 1990
PLATELET-INDUCED CLOT RETRACTION INHIBITS STREPTOKINASE (SK) BUT NOT TISSUE PLASMINOGEN-ACTIVATOR (T-PA) MEDIATED CLOT LYSIS 1990
PROGRESSION OF LEFT-VENTRICULAR DYSFUNCTION - REMODELING OR DEPRESSED CONTRACTILITY 1990
SOLUBLE FIBRIN DEGRADATION PRODUCTS POTENTIATE TISSUE PLASMINOGEN-ACTIVATOR (T-PA) INDUCED FIBRINOGENOLYSIS 1990
SYNERGISTIC ACTIONS OF NITROVASODILATORS AND ISOPROTERENOL ON RAT AORTIC SMOOTH-MUSCLE 1990
THORACIC AORTIC-SURGERY 1990
EFFECT OF ACUTE ANGIOTENSIN CONVERTING ENZYME-INHIBITION ON LEFT-VENTRICULAR FILLING IN PATIENTS WITH CONGESTIVE HEART-FAILURE - RELATION TO RIGHT VENTRICULAR VOLUMES 1990
CAN COLOR FLOW IMAGING PREDICT ATRIAL SEPTAL-DEFECT SHUNT SIZE 1987
DIFFERENCES IN TRENDS IN CONGESTIVE-HEART-FAILURE (CHF) DEATHS BY RACE AND AGE IN THE UNITED-STATES FROM 1968 TO 1978 1987
LEVEL OF NURSING-CARE REQUIRED BY THE UNSTABLE ANGINA PATIENT 1987
OPTIMAL LEVEL OF ANTICOAGULATION FOLLOWING TISSUE VALVE-REPLACEMENT - A RANDOMIZED TRIAL 1987
PREVALENCE OF LATE VENTRICULAR ARRHYTHMIA POSTMYOCARDIAL INFARCTION IN A DEFINED COMMUNITY 1987
DDAVP REDUCES THE PLATELET DEFECT ASSOCIATED WITH HEPARIN 1986
DOPPLER QUANTITATION OF DIASTOLIC FUNCTION DURING PTCA INDUCED ISCHEMIA 1986
ETHANOL INHIBITS THROMBIN-INDUCED INOSITOL TRISPHOSPHATE PRODUCTION BY RABBIT PLATELETS 1986
ISCHEMIC MYOCARDIAL LESIONS IN PREMATURE-INFANTS - ECHO DENSITY ANALYSIS AND PATHOLOGICAL CORRELATIONS 1986
MORTALITY AND MORBIDITY AFTER COMBINING RANDOMIZED TRIALS OF CARDIAC REHABILITATION 1986
NEUTROPHIL (PMN)-MEDIATED FIBRINOGEN PROTEOLYSIS IN THE PRESENCE OF PROTEINASE-INHIBITORS 1986
RANDOMIZED CONTROLLED TRIAL OF PK-10169 LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) FOR VENOUS THROMBOSIS PROPHYLAXIS AFTER ELECTIVE HIP-SURGERY 1986
THE EFFECTS OF LIDOCAINE ON VENTRICULAR-FIBRILLATION AND ASYSTOLE FOLLOWING SUSPECTED ACUTE MYOCARDIAL-INFARCTION 1986
A RANDOMIZED CONTROLLED TRIAL OF INTRAVENOUS HEPARIN FOR THE PREVENTION OF STROKE PROGRESSION IN ACUTE PARTIAL THROMBOTIC STROKE 1985
A RANDOMIZED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR FOR THE TREATMENT OF PROXIMAL DEEP-VEIN THROMBOSIS 1985
CENTRAL CARDIOVASCULAR FUNCTION BEFORE AND AFTER 4 YEARS OF EXERCISE FOLLOWING MYOCARDIAL-INFARCTION 1985
CHOLESTEROL-LOWERING TRIAL RESULTS IN THEIR EPIDEMIOLOGIC CONTEXT 1985
HOW RELIABLE ARE DOPPLER STUDIES IN THE ASSESSMENT OF PROSTHETIC MITRAL-VALVE DYSFUNCTION 1985
IV NITROGLYCERIN (NG) AND NITROPRUSSIDE (NP) THERAPY IN ACUTE MYOCARDIAL-INFARCTION REDUCES MORTALITY - EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS) 1985
MORPHOLOGICAL-CHANGES FOLLOWING CORONARY ANGIOPLASTY (PTCA) AND CAUSES OF RESTENOSIS 1985
ONE YEAR PROGNOSIS OF CCU PATIENTS - COMPLETE FOLLOW-UP FROM A COMMUNITY OF 375,000 PEOPLE 1985
PREVENTION OF MYOCARDIAL PLATELET DEPOSITION AND THROMBOXANE RELEASE DURING BYPASS-SURGERY WITH DIPYRIDAMOLE 1985
Q-WAVE DEVELOPMENT AND REGRESSION ONE YEAR FOLLOWING MYOCARDIAL-INFARCTION 1985
THE EFFECT OF INTRAVENOUS PROPAFENONE ON RAPID ATRIAL-FIBRILLATION 1985
12 LEAD ECG RECORDING DURING CORONARY ANGIOPLASTY (PTCA) - ANALYSIS OF RECIPROCAL CHANGES 1984
A CLINICAL COMPARISON OF CORONARY-BYPASS SURGERY PATIENTS AND CORONARY ANGIOPLASTY PATIENTS - A ONE YEAR FOLLOW-UP 1984
A STUDY OF ASPIRIN (ASA) AND OR SULFINPYRAZONE (S) IN UNSTABLE ANGINA (UA) 1984
ALTERED FETAL LAMB COAGULATION AFTER ADMINISTRATION OF LOW-MOLECULAR WEIGHT HEPARIN TO THE EWE 1984
BETA-BLOCKERS WITH INTRINSIC SYMPATHOMIMETIC ACTIVITY ARE LESS BENEFICIAL AFTER MYOCARDIAL-INFARCTION 1984
DOES TREATMENT OF CHRONIC HEART-FAILURE WITH ORAL VASODILATORS IMPROVE SURVIVAL 1984
EFFECTS OF LOW-MOLECULAR WEIGHT HEPARIN FRACTIONS ON INHIBITION OF THROMBUS GROWTH 1984
RELATIONSHIP OF APOLIPOPROTEINS AND RISK OF CARDIOVASCULAR DEATH - THE LIPID RESEARCH CLINICS PROGRAM FOLLOW-UP-STUDY 1984
SPECTRAL PHONOCARDIOGRAPHIC ASSESSMENT OF MECHANICAL PROSTHETIC HEART-VALVES 1984
SUSTAINED THERAPEUTIC HEPARINIZATION BY SUBCUTANEOUS ADMINISTRATION FOR THE PRIMARY-TREATMENT OF ACUTE VENOUS THROMBOSIS 1984
THROMBIN AND ADP DECREASE PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE IN WASHED RABBIT PLATELETS BY DIFFERENT MECHANISMS 1984
A ROLE FOR LUNG-SCANNING EARLY IN THE MANAGEMENT OF PATIENTS WITH PROXIMAL DEEP VENOUS THROMBOSIS 1983
CORONARY RISK-FACTORS AND EXERCISE TESTING IN HYPERCHOLESTEROLEMIC MEN 1982
PLATELET SURVIVAL AND PLASMA BETATHROMBOGLOBULIN AFTER HETEROGRAFT MITRAL-VALVE REPLACEMENT - EFFECT OF SULOCTIDIL 1982
A RANDOMIZED TRIAL OF TITRATED DOSE SUBCUTANEOUS (SC) HEPARIN VERSUS WARFARIN IN LONG-TERM TREATMENT OF PATIENTS WITH DEEP VENOUS THROMBOSIS (VT) 1980
AN EVALUATION OF THE RADIOIMMUNOASSAY FOR FRAGMENT-E IN THE DIAGNOSIS OF VENOUS THROMBOSIS IN CLINICALLY SYMPTOMATIC PATIENTS 1980
CALF AND THIGH COMPRESSION TO PREVENT VENOUS THROMBOSIS (VT) IN INTRA-CRANICAL DISEASE (ICD) 1980
CLINICAL-TRIAL OF LOW-DOSE HEPARIN FOR THE PREVENTION OF STROKE PROGRESSION 1980
EVALUATION OF GAMMA-FUNCTION CALCULATION OF PLATELET SURVIVAL-TIME (PST) 1980
PLASMA BETATHROMBOGLOBULIN (BTG) AND SERUM FRAGMENT-E (FGE) IN ACUTE PARTIAL STROKE 1980
PLASMAPHERESIS IS EFFECTIVE IN THROMBOTIC THROMBOCYTOPENIA PURPURA (TTP) BY ALTERING THE BINDING CHARACTERISTICS OF IMMUNE-COMPLEXES 1980
REPLACEMENT OF VENOGRAPHY IN SUSPECTED VENOUS THROMBOSIS BY IMPEDANCE PLETHYSMOGRAPHY AND FIBRINOGEN-I-125 LEG SCANNING 1980
SEX-RELATED DIFFERENCES IN PLATELET-FUNCTION INVIVO FOLLOWING ASPIRIN ADMINISTRATION 1980
THE INHIBITORY EFFECT OF ASPIRIN ON PLATELET-FUNCTION INDEPENDENT OF ACETYLATION OF CYCLO OXYGENASE 1980
THE RELATIONSHIP BETWEEN THE HEMORRHAGIC AND ANTI-THROMBOTIC EFFECTS OF STANDARD AND LOW-MOLECULAR WEIGHT (LMW) HEPARINS 1980
TOLAZOLINE HYDROCHLORIDE IN THE MANAGEMENT OF PATIENTS WITH LABILE PULMONARY VASCULAR-RESISTANCE FOLLOWING CARDIAC-SURGERY 1980
VAGAL EFFERENT DEPRESSION OF SEGMENTAL CONTRACTILITY DUE TO ACUTE POSTERIOR WALL ISCHEMIA 1980
MECHANISMS OF CLOSURE OF THE MITRAL-VALVE 1979
AFTERLOAD AND REFLEX REGULATION OF CARDIAC RESPONSE TO MYOCARDIAL ISCHEMIA 1978
COMPARATIVE EFFECTS OF SODIUM AND CALCIUM HEPARIN ON PLASMA HEPARIN CONCENTRATION, PARTIAL THROMBOPLASTIN TIME, PLATELET COUNT AND BLEEDING 1978
COMPARATIVE-STUDY OF DOPPLER ULTRASOUND (DP) AND IMPEDANCE PLETHYSMOGRAPHY (IPG) IN DIAGNOSIS OF SYMPTOMATIC AND ASYMPTOMATIC DEEP-VEIN THROMBOSIS (DVT) 1978
EFFECTIVENESS OF PULSATILE STOCKINGS FOR PREVENTION OF VENOUS THROMBOSIS AFTER ELECTIVE KNEE SURGERY 1978
ELECTROCARDIOGRAPHIC AND ENZYME EVOLUTION OF INFARCT SIZE IN MAN 1978
NEGATIVE CORRELATION BETWEEN PLATELET SURVIVAL, BETA-THROMBOGLOBULIN AND PLATELET AGGREGATE RATIO IN PATIENTS WITH CORONARY-ARTERY DISEASE 1978
INFARCT SIZE FROM SERIAL CPK - VARIABILITY OF SERUM ENTRY RATIO WITH INFARCT SIZE AND MODEL 1977
PREVENTION OF VENOUS THROMBOSIS BY INTERMITTENT CALF COMPRESSION IN PATIENTS WITH STROKES OR AFTER NEUROSURGERY 1977
PRIMARY PREVENTION OF CARDIOVASCULAR-DISEASE - SOCIAL PSYCHOLOGICAL PROGRAM TO REDUCE ONSET OF SMOKING AMONG CHILDREN 1977
THROMBOCYTOPENIA INDUCED BY BUSULFAN AND ANTIPLATELET SERUM INHIBITS AORTIC LESIONS CAUSED BY INJURY 1977
DETERMINANTS OF CLINICAL DECISION TO TREAT HYPERTENSION 1976
EFFECT OF VIRUSES ON PLATELET-AGGREGATION AND PLATELET SURVIVAL IN RABBITS 1976
IMPEDANCE PLETHYSMOGRAPHY (IPG) AND FIBRINOGEN-I-125 LEG SCANNING (LEG-SCAN) IN DIAGNOSIS OF CLINICALLY SUSPECTED DEEP VENOUS THROMBOSIS (DVT) 1976
RELATIONSHIP BETWEEN POSTOPERATIVE PULMONARY-EMBOLISM (PE) AND DEEP VENOUS THROMBOSIS (DVT) 1976
RELATIVE IMPORTANCE OF ATRIAL CONTRIBUTION TO CARDIAC-OUTPUT AT VARIOUS LEFT-VENTRICULAR FILLING PRESSURES 1976
STUDIES OF INTERACTION OF HEPARIN WITH THROMBIN AND ANTITHROMBIN-3 USING AFFINITY CHROMATOGRAPHIC TECHNIQUES 1976
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.. 150:1781-1790. 2024
Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial.. 150:1747-1755. 2024
Abstract 4116714: Macrophage Colony Stimulating Factor as a Causal Metabolic Mediator of Cardiovascular Disease: An Observational and Mendelian Randomization Analysis. 150:a4116714-a4116714. 2024
Abstract 4135791: Bleeding risk with non-vitamin K antagonist oral anticoagulants versus single antiplatelet therapy: A systematic review and meta-analysis of randomized controlled trials. 150:a4135791-a4135791. 2024
Abstract 4143723: Thrombocytosis is Prevalent and Associated with Greater Inflammation and Coronary Artery Involvement in Both Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Associated with COVID-19. 150:a4143723-a4143723. 2024
Cardiovascular Care in Canada: Strengths, Challenges, and Opportunities For Improvement.. 150:1490-1492. 2024
Topical Versus Intravenous Tranexamic Acid in Patients Undergoing Cardiac Surgery: The DEPOSITION Randomized Controlled Trial. 150:1315-1323. 2024
Response by McIntyre et al to Letter Regarding Article, "Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials".. 150:e274-e275. 2024
Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation. 150:1090-1100. 2024
Arterial Thrombosis: Present and Future.. 150:905-907. 2024
Cardiac Arrest and Cardiopulmonary Resuscitation Outcome Reports: 2024 Update of the Utstein Out-of-Hospital Cardiac Arrest Registry Template. 150:e203-e223. 2024
Implementation Science to Achieve Equity in Heart Failure Care: A Scientific Statement From the American Heart Association. 149:e1143-e1163. 2024
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD. 149:1536-1539. 2024
The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis. 149:1315-1318. 2024
Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials. 149:981-988. 2024
Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation. 149:932-943. 2024
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. 149:e347-e913. 2024
Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction. 149:510-520. 2024
Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD. 148:1919-1928. 2023
Abstract 14729: Association of Iliac Artery Non-Calcified Plaque Volume and Acute Limb Ischemia: Insights From the VOYAGER PAD Angiographic Core Lab. 148. 2023
Abstract 15474: Factors Associated With Shock at Presentation for Patients With Kawasaki Disease versus Multisystem Inflammatory Syndrome in Children Associated With COVID-19. 148. 2023
Abstract 16398: Impact of Low-Dose Rivaroxaban Plus Aspirin on Total Vascular Events in Fragile Patients With Peripheral Artery Disease: Insights From VOYAGER PAD. 148. 2023
Abstract 16428: Impact of Low-Dose Rivaroxaban Plus Aspirin on Myocardial Infarction in Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD. 148. 2023
Association Between Mental Health Burden, Clinical Presentation, and Outcomes in Individuals With Symptomatic Peripheral Artery Disease: A Scientific Statement From the American Heart Association. 148:1511-1528. 2023
Graft Failure After Coronary Artery Bypass Grafting and Its Association With Patient Characteristics and Clinical Events: A Pooled Individual Patient Data Analysis of Clinical Trials With Imaging Follow-Up. 148:1305-1315. 2023
Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III. 148:1298-1304. 2023
P-Selectin de-ACTIVation in COVID-19: What Have We Learned?. 148:391-393. 2023
Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study. 147:1872-1886. 2023
Letter by Wong and Demers Regarding Article, “Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial”. 147:1118-1118. 2023
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial. 147:1004-1013. 2023
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. 147:1026-1038. 2023
Randomized Trials Fit for the 21st Century: A Joint Opinion From the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. 147:925-929. 2023
Abstract P339: The Clinical Application and Ancestral Diversity of Cardiometabolic Polygenic Risk Scores. 147. 2023
2022 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces. 146:e483-e557. 2022
What Is the Future of Factor XI Inhibitors?. 146:1899-1902. 2022
Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and End-Stage Renal Disease: Lessons Learned. 146:1746-1748. 2022
2022 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces. 181:208-288. 2022
Abstract 10240: Lower May Not Be Better: Systolic Blood Pressure and Risk of Major Adverse Limb Events in Patients With Symptomatic Peripheral Artery Disease After Revascularization: Insights From Voyager Pad. 146:a10240-a10240. 2022
Abstract 10284: Alcohol Consumption and Cardiovascular Outcomes in Patients With Atrial Fibrillation; a RE-LY AF Registry Analysis. 146:a10284-a10284. 2022
Abstract 10889: Unplanned Limb Revascularization With Rivaroxaban versus Placebo in Patients With Critical Limb Ischemia After Endovascular and Surgical Treatment: Insights From Voyager Pad. 146:a10889-a10889. 2022
Abstract 11497: Mineralocorticoid Receptor Antagonists and Atrial Fibrillation: A Systematic Review and Meta-Analysis. 146:a11497-a11497. 2022
Abstract 12197: Causes of Death in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization: Insights From Voyager Pad. 146:a12197-a12197. 2022
Abstract 12680: Alcohol Consumption and Arrhythmia Recurrence After Atrial Fibrillation Ablation: A Systematic Review and Meta-Analysis. 146:a12680-a12680. 2022
Abstract 14114: Sex Differences in the Etiology and Burden of Heart Failure Across the Sociodemographic Index: Analysis of 204 Countries and Territories, 1990-2019. 146:a14114-a14114. 2022
Abstract 14157: Effects of Follistatin on the Regulation of Vascular Function by Perivascular Adipose Tissue in a Model of Essential Hypertension. 146:a14157-a14157. 2022
Abstract 9928: Risk Stratification for Amputation in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. 146:a9928-a9928. 2022
Consumer-Led Screening for Atrial Fibrillation: Frontier Review of the AF-SCREEN International Collaboration. 146:1461-1474. 2022
Effects on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: Meta-Analysis of Individual Patient Data From 7 Multicenter Randomized Clinical Trials. 146:1329-1343. 2022
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. 146:1196-1206. 2022
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.. 146:657-672. 2022
Response by Lam and Gerstein to Letter Regarding Article, “Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial”. 146:e7. 2022
Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. 145:1875-1877. 2022
Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. 145:1693-1704. 2022
Shouldn’t Preventing Type 2 Diabetes Also Prevent Its Long-Term Consequences?. 145:1642-1644. 2022
Letter by Ibrahim et al Regarding Article, “Anterior–Lateral Versus Anterior–Posterior Electrode Position for Cardioverting Atrial Fibrillation”. 145:e1056. 2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. 145:1471-1479. 2022
2021 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Neonatal Life Support; Education, Implementation, and Teams; First Aid Task Forces; and the COVID-19 Working Group. 145:e645-e721. 2022
Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. 145:693-712. 2022
Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. 145:565-574. 2022
Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2. 145:626-628. 2022
Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration. 145:392-409. 2022
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. 145:242-255. 2022
Epigenetic Age and the Risk of Incident Atrial Fibrillation. 144:1899-1911. 2021
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. 144:1831-1841. 2021
Abstract 10249: Association of Eligibility for a Sodium-Glucose Co-Transporter 2 Inhibitor and Cardiovascular Outcomes in Patients with Atrial Fibrillation. 144:a10249-a10249. 2021
Abstract 11042: New-Onset Atrial Fibrillation After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis. 144:a11042-a11042. 2021
Abstract 12651: Non-Pharmacological Interventions to Improve Electrical Cardioversion Success in Patients With Atrial Fibrillation: A Scoping Review. 144:a12651-a12651. 2021
Abstract 13644: Depict Analysis Suggests Enrichment of Heart Valve Tissue Expression in African Rheumatic Heart Disease Patients From the RHDGen GWAS Study Cohort. 144:a13644-a13644. 2021
Diagnosis and Management of Patients With Myocardial Injury After Noncardiac Surgery: A Scientific Statement From the American Heart Association. 144:e287-e305. 2021
Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. 144:1104-1116. 2021
Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study. 144:1133-1144. 2021
Letter by Hwang et al Regarding Article, “Temporal Release of High-Sensitivity Cardiac Troponin T and I and Copeptin After Brief Induced Coronary Artery Balloon Occlusion in Humans”. 144:e166-e167. 2021
Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. 143:2129-2142. 2021
Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation. 143:1863-1873. 2021
Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease:. 143:1468-1480. 2021
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. 143:583-596. 2021
Research Priorities in Atrial Fibrillation Screening. 143:372-388. 2021
Letter by Belley-Côté and Whitlock Regarding Article, “Impact of Left Atrial Appendage Exclusion on Short-Term Outcomes in Isolated Coronary Artery Bypass Graft Surgery”. 142:e503. 2020
Stroke Prevention in Atrial Fibrillation. 142:2371-2388. 2020
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. 142:2219-2230. 2020
Abstract 13474: Rivaroxaban Reduces Major Cardiovascular and Limb Events in Patients With the High-risk Triad of Chronic Kidney Disease, Peripheral Artery Disease and Recent Lower Extremity Revascularization: Insights From VOYAGER PAD. 142. 2020
Abstract 14170: Reduction in Venous Thromboembolism With Rivaroxaban versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. 142. 2020
Abstract 14882: Outcomes of Heart Failure in Hypoplastic Left Heart Syndrome and the Impact of Recovery. 142. 2020
Abstract 15586: Burden of Cardiovascular or Fatal Outcomes in People With Type 2 Diabetes and Cardiovascular Risk Factors Treated With Dulaglutide a Post Hoc Analysis From the Rewind Trial. 142. 2020
Abstract 16544: Small Rna-sequencing Analysis of Circulating Proinflammatory Microrna Following Murine Myocardial Ischemia/reperfusion Injury. 142. 2020
Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral Anticoagulation. 142:1697-1699. 2020
Adult Advanced Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. 142:S92-S139. 2020
Evidence Evaluation Process and Management of Potential Conflicts of Interest: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. 142:S28-S40. 2020
An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2 -Catecholaminergic Polymorphic Ventricular Tachycardia. 142:932-947. 2020
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. 142:621-642. 2020
Association of Factor V Leiden With Subsequent Atherothrombotic Events. 142:546-555. 2020
Hospitalized COVID-19 Patients and Venous Thromboembolism. 142:129-132. 2020
The COMPASS Trial. 142:40-48. 2020
Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association. 141:e914-e931. 2020
Resource and Infrastructure-Appropriate Management of ST-Segment Elevation Myocardial Infarction in Low- and Middle-Income Countries. 141:2004-2025. 2020
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. 141:1841-1854. 2020
Prothrombin Complex Concentrates for Intracranial Hemorrhage on Factor Xa Inhibitors. 141:1690-1692. 2020
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). 141:1141-1151. 2020
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. 141:843-862. 2020
How Did We Get Here?: A Historical Review and Critical Analysis of Anticoagulation Therapy Following Mechanical Valve Replacement. 140:1933-1942. 2019
Searching for Atrial Fibrillation Poststroke. 140:1834-1850. 2019
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. 140:1578-1589. 2019
Cardiac Arrest and Cardiopulmonary Resuscitation Outcome Reports: Update of the Utstein Resuscitation Registry Template for In-Hospital Cardiac Arrest. 144:166-177. 2019
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. 140:1451-1459. 2019
Cardiac Arrest and Cardiopulmonary Resuscitation Outcome Reports: Update of the Utstein Resuscitation Registry Template for In-Hospital Cardiac Arrest: A Consensus Report From a Task Force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian and New Zealand Council on Resuscitation, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Southern Africa, Resuscitation Council of Asia). 140:e746-e757. 2019
Novel Drug Targets for Ischemic Stroke Identified Through Mendelian Randomization Analysis of the Blood Proteome. 140:819-830. 2019
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. 140:529-537. 2019
Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. 140:420-433. 2019
Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. 140:240-261. 2019
Effect of Alirocumab on Mortality After Acute Coronary Syndromes. 140:103-112. 2019
Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. 139:2846-2856. 2019
Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. 139:2170-2185. 2019
Hyperglycemia-Driven Inhibition of AMP-Activated Protein Kinase α2 Induces Diabetic Cardiomyopathy by Promoting Mitochondria-Associated Endoplasmic Reticulum Membranes In Vivo. 139:1913-1936. 2019
Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. 139:1472-1482. 2019
Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis. 139:1162-1173. 2019
Sex-Related Differences in Patients Undergoing Thoracic Aortic Surgery. 139:1177-1184. 2019
Stroke Outcomes in the COMPASS Trial. 139:1134-1145. 2019
Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. 139:787-798. 2019
Moyamoya Disease Susceptibility Variant RNF213 p.R4810K Increases the Risk of Ischemic Stroke Attributable to Large-Artery Atherosclerosis. 139:295-298. 2019
Timing of Intervention in Non-ST Elevation Acute Coronary Syndromes. 138:2751-2753. 2018
2018 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations Summary. 138:e714-e730. 2018
Malnutrition and Mortality in Frail and Non-Frail Older Adults Undergoing Aortic Valve Replacement. 138:2202-2211. 2018
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. 138:1963-1973. 2018
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. 138:527-536. 2018
ILCOR Scientific Knowledge Gaps and Clinical Research Priorities for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: A Consensus Statement. 137:e802-e819. 2018
Suboptimal Outcome of Myocardial Infarction After Noncardiac Surgery. 137:2340-2343. 2018
Letter by Graudal and Mente Regarding Article, “Use of a Single Baseline Versus Multiyear 24-Hour Urine Collection for Estimation of Long-Term Sodium Intake and Associated Cardiovascular and Renal Risk”. 137:1536-1537. 2018
Abstract P171: The “Hub and Spoke” Model of Heart Function Care Achieves Quality Index Markers. 137. 2018
Abstract P253: Adiposity Indicators and Blood Pressure in South Asian Children and Adolescents. 137. 2018
Response by Kusters et al to Letter Regarding Article, “Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)”. 137:641-642. 2018
Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention. 137:307-309. 2018
Risks of Overinterpreting Interim Data. 137:206-209. 2018
Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization. 137:88-90. 2018
Timing of Angiography and Outcomes in High-Risk Patients With Non–ST-Segment–Elevation Myocardial Infarction Managed Invasively. 136:1895-1907. 2017
Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. 136:1560-1562. 2017
Subclinical Atrial Fibrillation in Older Patients. 136:1276-1283. 2017
Response by Parkash et al to Letters Regarding Article, “Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control])”. 136:1271-1272. 2017
Genetic Testing in the Evaluation of Unexplained Cardiac Arrest From the CASPER (Cardiac Arrest Survivors With Preserved Ejection Fraction Registry). 136:872-872. 2017
Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia. 136:359-366. 2017
Response by Jolly et al to Letters Regarding Article, “Thrombus Aspiration in ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy Trialists Collaboration”. 135:e1103-e1104. 2017
Primary Prevention With Statin Therapy in the Elderly. 135:1979-1981. 2017
Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation. 135:1788-1798. 2017
Screening for Atrial Fibrillation. 135:1851-1867. 2017
Response by Than et al to Letter Regarding Article, “Assessment of the European Society of Cardiology 0-Hour/1-Hour Algorithm to Rule-Out and Rule-In Acute Myocardial Infarction”. 135:e923-e924. 2017
Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. 135:1273-1275. 2017
Abstract P171: Potential Mortality Reduction with Optimal Usage of sacubitril/valsartan Therapy for the Treatment of Heart Failure in Canada. 135. 2017
Response by Smyth et al to Letters Regarding Article, “Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study”. 135:e644-e645. 2017
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. 135:724-735. 2017
Is There a Role for Betrixaban to Prevent Stroke in Medically Ill Patients?. 135:656-658. 2017
Number of Pregnancies and Atrial Fibrillation Risk. 135:622-624. 2017
Thrombus Aspiration in ST-Segment–Elevation Myocardial Infarction. 135:143-152. 2017
Smoking. 135:17-20. 2017
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. 134:1697-1707. 2016
Response by Weitz and Eikelboom to Letter Regarding Article, “Urgent Need to Measure Effects of Direct Oral Anticoagulants”. 134:e498. 2016
Assessment of the European Society of Cardiology 0-Hour/1-Hour Algorithm to Rule-Out and Rule-In Acute Myocardial Infarction. 134:1532-1541. 2016
Abstract 12442: Exception to Consent in Pediatric Resuscitation Research: Exploring the Experiences of Substitute Decision Makers. 134. 2016
Clinical Outcomes in 3343 Children and Adults With Rheumatic Heart Disease From 14 Low- and Middle-Income Countries. 134:1456-1466. 2016
Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target?. 134:1311-1313. 2016
Point-of-Care Hemostatic Testing in Cardiac Surgery. 134:1152-1162. 2016
Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction. 134:1059-1067. 2016
Response by Bagai et al to Letter Regarding Article, “Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention”. 134:e334-e335. 2016
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. 134:589-598. 2016
Letter by Hess et al Regarding Article, “How to Manage Occult Atrial Fibrillation Detected on Long-Term Monitoring”. 134:e28-e29. 2016
Urgent Need to Measure Effects of Direct Oral Anticoagulants. 134:186-188. 2016
Double Trouble. 133:2206-2211. 2016
Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. 133:2094-2098. 2016
Abstract P009: Risk of Mortality According to Burden of Atrial Fibrillation: Results From a 60-year Cohort Study. 133. 2016
Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. 133:742-755. 2016
Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. 133:21-30. 2016
Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. 132:2297-2304. 2015
Idarucizumab. 132:2412-2422. 2015
Abstract 13635: Atorvastatin for the Prevention of Major Vascular Events in Patients Undergoing Non-Cardiac Surgery: The LOAD-Pilot Randomized Clinical Trial. 132. 2015
Abstract 14295: Increasing QRS Duration Over Time Is Associated With Mortality and Morbidity in an Outpatient Heart Failure Population. 132. 2015
Abstract 14299: The Prognostic Value of Insulin-like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Ejection Fraction: Results From Irbesartan in Heart Failure and Preserved Ejection Fraction (I-PRESERVE) Trial. 132. 2015
Abstract 17354: A Canadian Pilot Randomized Controlled Trial for a Decision Support Intervention in de novo Implantable Cardioverter Defibrillator Candidates - Main findings. 132. 2015
Abstract 18025: Systematic Screening is Necessary to Detect Post-operative Thrombosis and Evaluate Risk in Children Undergoing Cardiac Surgery: A Prospective Observational Study. 132. 2015
Abstract 18045: Mild Coarctation of the Aorta: To Touch or Not to Touch the Patient? Looking at Left Ventricular Function and Hemodynamics. 132. 2015
Abstract 18061: Supplementation to Treat Antithrombin Deficiency Improves Sensitivity to Heparin, Anticoagulation and Decreased Thrombogenecity in Neonates and Infants Undergoing Cardiac Surgery With Cardiopulmonary Bypass. 132. 2015
Abstract 18760: Evaluation of a Web-based Cardiac Pain Knowledge Dissemination Platform Fueled by Social Media. 132. 2015
Abstract 19878: Burden of Systolic and Diastolic Left Ventricular Dysfunction Among Hispanics in the United States - Insights From the Echocardiographic Study of Latinos (ECHO-SOL). 132. 2015
Response to Letter Regarding Article, “Left Atrial Appendage Occlusion Debate Revisited”. 132:e230. 2015
Part 2: Evidence Evaluation and Management of Conflicts of Interest. 132:S368-S382. 2015
Part 4: Systems of Care and Continuous Quality Improvement. 132:S397-S413. 2015
Part 9: Acute Coronary Syndromes. 132:S483-S500. 2015
Part 1: Executive Summary. 132:S2-39. 2015
Part 5: Acute Coronary Syndromes. 132:S146-S176. 2015
Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support. 132:S177-S203. 2015
Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation. 132:796-803. 2015
Influence of Baseline Characteristics, Operative Conduct, and Postoperative Course on 30-Day Outcomes of Coronary Artery Bypass Grafting Among Patients With Left Ventricular Dysfunction. 132:720-730. 2015
Perioperative Management of Dabigatran. 132:167-173. 2015
Young Women With Acute Myocardial Infarction and the Posthospital Syndrome. 132:149-151. 2015
Are We Ready for Mass Screening to Detect Atrial Fibrillation?. 131:2167-2168. 2015
Now You See It, Now You Don’t?. 131:1872-1879. 2015
Left Atrial Appendage Occlusion Debate Revisited. 131:756-761. 2015
Response to Letter Regarding Article “Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events”. 131:e337-e338. 2015
International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. 131:43-53. 2015
Abstract 16393: Right Ventricular Energetics and Power in Pulmonary Regurgitation vs. Stenosis Using Four-Dimensional Phase-Contrast Magnetic Resonance. 130. 2014
Response to Letter Regarding Article, “Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis”. 130:e195. 2014
The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies. 130:1636-1661. 2014
Challenges and Priorities for Research. 130:1192-1203. 2014
Aspirin for the Prevention of Recurrent Venous Thromboembolism. 130:1062-1071. 2014
Response to Letter Regarding Article, “Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin”. 130:e95. 2014
Response to Letter Regarding Article, “Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study”. 130:e85. 2014
Patterns of Alcohol Consumption and Myocardial Infarction Risk. 130:390-398. 2014
A Noncompaction Reaction. 129:2171-2178. 2014
Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. 129:2094-2099. 2014
Management of Anticoagulation Around Pacemaker and Defibrillator Surgery. 129:2062-2065. 2014
Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. 129:1850-1859. 2014
Periprocedural Management of New Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation. 129:1688-1694. 2014
Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. 129:1568-1576. 2014
Documenting the Global Burden of Cardiovascular Disease. 129:1459-1462. 2014
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. 129:961-970. 2014
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. 129:764-772. 2014
Response to Letter Regarding Article, “Survival After Implantable Cardioverter-Defibrillator Implantation in the Elderly”. 129:e337-e338. 2014
Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies. 129:28-41. 2014
Abstract 18333: Tdag51 Deficiency Protects Against Aortic Vascular Calcification by Attenuating Smooth Muscle Cell Death and Osteoblastic Trans-Differentiation. 128. 2013
Abstract 197: Rapid Pediatric Fluid Resuscitation: A Randomized Controlled Trial Comparing the Efficiency of Two Provider Endorsed Manual Fluid Resuscitation Techniques. 128. 2013
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. 128:2325-2332. 2013
Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. 128:2192-2201. 2013
Four-Factor Prothrombin Complex Concentrate for Urgent Reversal of Vitamin K Antagonists in Patients With Major Bleeding. 128:1179-1181. 2013
Rosiglitazone and Cardiovascular Outcomes. 128:777-779. 2013
Right Ventricular Tachycardia. 128:e85-e87. 2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. 128:237-243. 2013
Decreased Endogenous Production of Hydrogen Sulfide Accelerates Atherosclerosis. 127:2523-2534. 2013
Cost-Effectiveness of Ventricular Assist Device Therapy as a Bridge to Transplantation Compared With Nonbridged Cardiac Recipients. 127:2424-2435. 2013
Survival After Implantable Cardioverter-Defibrillator Implantation in the Elderly. 127:2383-2392. 2013
Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding. 127:1404-1412. 2013
Response to Letters Regarding Article, “Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”. 127:E506-E506. 2013
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.. 127:e506. 2013
Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. 127:634-640. 2013
Permanent Cardiac Pacing in Children: Choosing the Optimal Pacing Site. 127:613-623. 2013
Response to Letter Regarding Article, “Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy”. 127:e278-e279. 2013
Relationship Between Healthy Diet and Risk of Cardiovascular Disease Among Patients on Drug Therapies for Secondary Prevention. 126:2705-2712. 2012
Abstract 18993: High Prevalence of Cognitive Impairment in Older Heart Failure Patients at Hospital Discharge. 126. 2012
Abstract 19004: Sr-bi Deficiency is Associated with Dendritic Cell Retention in Arterial Atherosclerotic Plagues and Impaired Atherosclerotic Regression in Apoe-r61 Hypomorphic Mice. 126. 2012
Abstract 9654: Dipeptidyl Peptidase-4 Inhibitors May Reduce the Risk of Major Adverse Cardiovascular Events and All-cause Mortality In Patients With Type 2 Diabetes: Meta-analyses Oof Randomized Controlled Trials. 126. 2012
Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation. 126:2381-2391. 2012
Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran. 126:2428-2432. 2012
Premature Atrial Contractions in the General Population. 126:2302-2308. 2012
Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries. 126:2309-2316. 2012
A Bloody Mass. 126:1923-1931. 2012
Guided Antithrombotic Therapy: Current Status and Future Research Direction. 126:1645-1662. 2012
Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists. 126:1630-1639. 2012
Risk of Elective Major Noncardiac Surgery After Coronary Stent Insertion. 126:1355-1362. 2012
Correction. 126:E160-E160. 2012
Impact of Sex on Cardiovascular Outcome in Patients at High Cardiovascular Risk. 126:934-941. 2012
Response to Letters Regarding Article, “Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction”. 126:E64-E65. 2012
Influenza Vaccination and Major Adverse Vascular Events in High-Risk Patients. 126:278-286. 2012
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. 126:343-348. 2012
Response to Letter Regarding Article, “Management of Severe Mitral Stenosis During Pregnancy”. 126:E16-E16. 2012
Reversal of Warfarin. 125:2944-2947. 2012
Influence of Mitral Regurgitation Repair on Survival in the Surgical Treatment for Ischemic Heart Failure Trial. 125:2639-2648. 2012
Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. 125:1605-1616. 2012
Bridging Anticoagulation. 125:e496-e498. 2012
Preoperative Serum Brain Natriuretic Peptide and Risk of Acute Kidney Injury After Cardiac Surgery. 125:1347-1355. 2012
Abstract P056: Fructose Intake May Decrease Diastolic and Mean Arterial Blood Pressure: A Systematic Review and Meta-analysis of Controlled Feeding Trials. 125. 2012
Aspirin. 125:e439-e442. 2012
Clinical Predictors of Fidelis Lead Failure. 125:1217-1225. 2012
Letter by Kavsak and MacRae Regarding Article, “Utility of Absolute and Relative Changes in Cardiac Troponin Concentrations in the Early Diagnosis of Acute Myocardial Infarction”. 125:e358. 2012
Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. 125:669-676. 2012
Reply to Letters Regarding Article, “Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial”. 125:E293-E294. 2012
Management of Severe Mitral Stenosis During Pregnancy. 124:2756-2760. 2011
Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction. 124:2491-2501. 2011
Abstract 8500: Alcohol Effect on Incident Atrial Fibrillation in Individuals with Cardiovascular Disease: Analysis of Data from the ONTARGET and TRANSCEND Studies. 124. 2011
Derivation and Validation of a Simple Exercise-Based Algorithm for Prediction of Genetic Testing in Relatives of LQTS Probands. 124:2187-2194. 2011
Statins and Intracerebral Hemorrhage. 124:2233-2242. 2011
Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). 124:1727-1736. 2011
Risk, Clinical Features, and Outcomes of Thrombosis Associated With Pediatric Cardiac Surgery. 124:1511-1519. 2011
Epidermal Growth Factor–Like Domain 7 Is a Novel Inhibitor of Neutrophil Adhesion to Coronary Artery Endothelial Cells Injured by Calcineurin Inhibition. 124:S197-S203. 2011
Importance of Family History as a Risk Factor for Venous Thromboembolism. 124:996-997. 2011
Standardized Bleeding Definitions for Cardiovascular Clinical Trials. 123:2736-2747. 2011
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. 123:2363-2372. 2011
Dabigatran Etexilate. 123:1436-1450. 2011
Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk. 123:1098-1107. 2011
Response to Letter Regarding Article, “Complications Associated With Revision of Sprint Fidelis Leads: Report From the Canadian Heart Rhythm Society Device Advisory Committee”. 123:E376-E377. 2011
IScore. 123:739-749. 2011
Meta-Analysis of Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive Protein Levels. 123:731-738. 2011
Letter by Kavsak et al Regarding Article, “B-Type Natriuretic Peptide Signal Peptide Circulates in Human Blood: Evaluation as a Potential Biomarker of Cardiac Ischemia”. 123:e233. 2011
Echo-Guided Pericardiocentesis. 123:e210-e211. 2011
Serious Cardiovascular Outcomes in Diabetes. 123:342-348. 2011
Dabigatran Versus Warfarin in Patients With Atrial Fibrillation. 123:131-136. 2011
Microvascular Function Predicts Cardiovascular Events in Primary Prevention. 123:163-169. 2011
Mechanisms Underlying the Lack of Effect of Implantable Cardioverter-Defibrillator Therapy on Mortality in High-Risk Patients With Recent Myocardial Infarction. 122:2645-2652. 2010
Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation. 122:2246-2253. 2010
The Polypill in the Prevention of Cardiovascular Diseases. 122:2078-2088. 2010
Titin is a Target of Matrix Metalloproteinase-2. 122:2039-2047. 2010
Improved Outcomes With Early Collaborative Care of Ambulatory Heart Failure Patients Discharged From the Emergency Department. 122:1806-1814. 2010
Epsilon Waves During Ventricular Tachycardia in a Case of Arrhythmogenic Right Ventricular Dysplasia. 122:1752-1755. 2010
Part 9: Acute Coronary Syndromes. 122:S422-S465. 2010
Right Ventricular Ischemic Injury in Patients With Acute ST-Segment Elevation Myocardial Infarction. 122:1405-1412. 2010
Birth Weight Is a Significant Risk Factor for Incident Atrial Fibrillation. 122:764-770. 2010
Brugada-Type Electrocardiographic Changes Induced by Long-Term Lithium Use. 122:e418-e419. 2010
Response to Letter Regarding Article, “Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction”. 122:E397-E397. 2010
Complications Associated With Revision of Sprint Fidelis Leads. 121:2384-2387. 2010
Triple Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Stents. 121:2067-2070. 2010
Response to Letter Regarding Article, “Donor Pretreatment With Hypertonic Saline Attenuates Primary Allograft Dysfunction: A Pilot Study in a Porcine Model”. 121:E394-E394. 2010
Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children. 121:1838-1847. 2010
New Anticoagulants. 121:1523-1532. 2010
Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both. 121:1439-1446. 2010
Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction. 121:1393-1405. 2010
Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. 121:1176-1187. 2010
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. 121:1188-1199. 2010
Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes. 121:750-758. 2010
Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis. 121:306-314. 2010
Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction. 120:2429-2437. 2009
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials. 120:2006-2011. 2009
Response to Letter Regarding Article, “Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial”. 120:E165-E165. 2009
Left Atrial Appendage Occlusion Does Not Eliminate the Need for Warfarin. 120:1927-1932. 2009
Left Atrial Appendage Occlusion Eliminates the Need for Warfarin. 120:1919-1926. 2009
Left Atrial Appendage Occlusion Eliminates the Need for Warfarin Response to Holmes and Schwartz. 120:1926-1926. 2009
Abstract 5795: Impact of the Modified Henry Ford Warfarin Maintenance Dosing Algorithm on Quality of Anticoagulation at a Specialist Anticoagulation Clinic. 120. 2009
Pectus Excavatum With Compression of the Inferior Vena Cava. 120:1722-1724. 2009
Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. 120:1380-1389. 2009
Accelerated Infusion of Streptokinase for the Treatment of Left-Sided Prosthetic Valve Thrombosis. 120:1108-1114. 2009
Donor Pretreatment With Hypertonic Saline Attenuates Primary Allograft Dysfunction. 120:S206-S214. 2009
Systematic Assessment of Patients With Unexplained Cardiac Arrest. 120:278-285. 2009
Response to Letter Regarding Article, “Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk”. 119:E595-E596. 2009
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. 119:2877-2885. 2009
Adverse Prognostic Significance of Thrombocytopenia in Acute Coronary Syndrome. 119:2420-2422. 2009
Influence of Systolic and Diastolic Blood Pressure on the Risk of Incident Atrial Fibrillation in Women. 119:2146-2152. 2009
High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus. 119:2103-2111. 2009
Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure. 119:1616-1624. 2009
Anticoagulation for ST-Segment Elevation Myocardial Infarction. 119:1186-1188. 2009
Thirty-Year Trends (1975 to 2005) in the Magnitude of, Management of, and Hospital Death Rates Associated With Cardiogenic Shock in Patients With Acute Myocardial Infarction. 119:1211-1219. 2009
Dysglycemia and Cardiovascular Risk in the General Population. 119:773-775. 2009
Acute Kidney Injury After Cardiac Surgery. 119:495-502. 2009
Response to Letters Regarding Article, “Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy”. 118:E840-E841. 2008
Fluoroscopy of Acutely Thrombosed Aortic Valve. 118:e705. 2008
Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non–ST-Segment Elevation Acute Coronary Syndromes. 118:2038-2046. 2008
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. 118:2029-2037. 2008
Dietary Patterns and the Risk of Acute Myocardial Infarction in 52 Countries. 118:1929-1937. 2008
Abstract 2598: Individualized Heparin and Protamine Management Protocol in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery Improves Immediate Post-operative Clinical Outcomes. 118. 2008
Abstract 4301: Chimeric Mice Lacking Microsomal Prostaglandin E ₂ Synthase-1 (mPGES) In Bone Marrow Develop Adverse Left Ventricular Remodelling After Myocardial Infarction. 118. 2008
Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid. 118:1705-1712. 2008
Impact of Inherited Thrombophilia on Venous Thromboembolism in Children. 118:1373-1382. 2008
Comprehensive Canadian Review of the Off-Label Use of Recombinant Activated Factor VII in Cardiac Surgery. 118:331-338. 2008
Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral Therapy. 118:e29-e35. 2008
Response to Letter Regarding Article, “Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure”. 118:E8-E8. 2008
Liquefaction Necrosis of Mitral Annulus Calcification. 117:e292-e294. 2008
Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden. 117:1283-1291. 2008
Response to Letter Regarding Article, “Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation”. 117:E150-E150. 2008
Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction?. 116:2793-2801. 2007
Abstract 1312: Dietary Supplementation With Sodium Valproate Attenuates Lesion Development In Hyperglycemic Apolipoprotein E-deficient Mice. 116. 2007
Abstract 3148: Atrial Fibrillation Is Associated With Increased Risk Of Fatal And Non-fatal Cardiovascular Events In Patients With Heart Failure And Preserved Ejection Fraction - Findings From The Irbesartan In Heart Failure With Preserved Systolic Function Trial (I-PRESERVE). 116. 2007
Abstract 3631: Elevated In-hospital Glucose Level, and not Known History of Diabetes Mellitus, Predicts 30-day Mortality Following Acute ST-elevation Myocardial Infarction. 116. 2007
Abstract 3640: Diabetes Mellitus is Associated with Increased Risk of Fatal and Non-Fatal Cardiovascular Events in Heart Failure Patients with Preserved Ejection Fraction - Findings From the Irbesartan in Heart Failure with Preserved Systolic Function Trial. 116. 2007
Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. 116:1482-1487. 2007
Increased Endoplasmic Reticulum Stress in Atherosclerotic Plaques Associated With Acute Coronary Syndrome. 116:1214-1216. 2007
Body Mass Index and Prognosis in Patients With Chronic Heart Failure. 116:627-636. 2007
Beyond Unfractionated Heparin and Warfarin. 116:552-560. 2007
Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation. 116:449-455. 2007
A Replacement for Warfarin. 116:131-133. 2007
Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure. 115:3111-3120. 2007
Response to Letter Regarding Article, “The Inflammatory Hypothesis: Any Progress in Risk Stratification and Therapeutic Targets?”. 115:E476-E476. 2007
Images in cardiovascular medicine. Left atrial-esophageal fistula after pulmonary vein isolation: a cautionary tale.. 115:e432-e433. 2007
Defining Obesity Cut Points in a Multiethnic Population. 115:2111-2118. 2007
Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk. 115:1371-1375. 2007
Risk Factors for Acute Myocardial Infarction in Latin America. 115:1067-1074. 2007
Regional Differences in Process of Care and Outcomes for Older Acute Myocardial Infarction Patients in the United States and Ontario, Canada. 115:196-203. 2007
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. 115:114-126. 2007
Primary prevention of ischemic stroke: a guideline from the American heart association/American stroke association stroke council (vol 113, pg 873, 2006). 114:E617-E617. 2006
Proteasomal Regulation of Cardiac Hypertrophy. 114:1796-1798. 2006
The Inflammatory Hypothesis. 114:1557-1560. 2006
Unmasking of the Brugada Syndrome Phenotype During the Acute Phase of Amiodarone Infusion. 114:e489-e491. 2006
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes. 114:774-782. 2006
Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. 114:774-782. 2006
Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study. 114:201-208. 2006
Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold. 114:104-109. 2006
Cardiovascular Outcomes With Atrial-Based Pacing Compared With Ventricular Pacing. 114:11-17. 2006
Predictors of Early Neurocognitive Deficits in Low-Risk Patients Undergoing On-Pump Coronary Artery Bypass Surgery. 114:I461-I466. 2006
Preventing Vascular Events Due to Elevated Blood Pressure. 113:2166-2168. 2006
Preventing vascular events due to elevated blood pressure. 113:2166-2168. 2006
Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure. 113:986-994. 2006
Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. 113:671-678. 2006
Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction. 112:3855-3867. 2005
Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients. 112:3738-3744. 2005
Risk Factors Associated With Myocardial Infarction in Africa. 112:3554-3561. 2005
Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes. 112:1339-1346. 2005
Should Aspirin Be Discontinued Before Coronary Artery Bypass Surgery?. 112:e85-e90. 2005
Coagulation Assays. 112:e53-e60. 2005
Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure. 112:48-53. 2005
Magnitude of and Risk Factors for In-Hospital and Postdischarge Stroke in Patients With Acute Coronary Syndromes. 111:3242-3247. 2005
Letters Regarding Article by Mehilli et al, "Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel" * Response. 111:e370-e371. 2005
Activation of the Unfolded Protein Response Occurs at All Stages of Atherosclerotic Lesion Development in Apolipoprotein E–Deficient Mice. 111:1814-1821. 2005
Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention. 111:1390-1397. 2005
Prevention of Venous Thromboembolism Among Hospitalized Medical Patients. 111:e1-e3. 2005
Anomalous Origin of the Left Coronary Artery From the Main Pulmonary Artery in Adults. 110:e511-e513. 2004
Assessment of Systemic Right Ventricular Function in Patients With Transposition of the Great Arteries Using the Myocardial Performance Index. 110:3229-3233. 2004
Weight Loss–Associated Induction of Peroxisome Proliferator–Activated Receptor-α and Peroxisome Proliferator–Activated Receptor-γ Correlate With Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice. 110:3259-3269. 2004
Heparin-Induced Thrombocytopenia. 110:e454-e458. 2004
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. 110:2618-2626. 2004
Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients. 110:2180-2183. 2004
Human Study of Biatrial Electrical Coupling. 110:2083-2089. 2004
Single-Arm Study of Bridging Therapy With Low-Molecular-Weight Heparin for Patients at Risk of Arterial Embolism Who Require Temporary Interruption of Warfarin. 110:1658-1663. 2004
Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction. 110:1413-1417. 2004
Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome. 110:1202-1208. 2004
Management of Venous Thromboembolism: Present and Future. 110:I2. 2004
New Anticoagulants for Treatment of Venous Thromboembolism. 110:I19-I26. 2004
Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. 110:874-879. 2004
Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism. 110:744-749. 2004
Association of Multiple Cellular Stress Pathways With Accelerated Atherosclerosis in Hyperhomocysteinemic Apolipoprotein E-Deficient Mice. 110:207-213. 2004
Principles for National and Regional Guidelines on Cardiovascular Disease Prevention. 109:3112-3121. 2004
Coronary Bypass Surgery Performed off Pump Does Not Result in Lower In-Hospital Morbidity Than Coronary Artery Bypass Grafting Performed on Pump. 109:887-892. 2004
Canadian Trial of Physiological Pacing. 109:357-362. 2004
Indications for Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in Chronic Stable Angina. 108:2439-2445. 2003
Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation. 108:2041-2048. 2003
Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes. 108:1682-1687. 2003
Clopidogrel in acute coronary syndromes: Can the cost effectiveness improve? Response. 108:E56-E56. 2003
Caffeine and Coffee Tolerance. 108:e38-e40. 2003
Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease. 108:420-425. 2003
Cardiac resynchronization and myocardial oxidative metabolism - Response. 107:E220-E220. 2003
Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin. 107:2884-2888. 2003
Risk Factors for Venous Thromboembolism. 107:I9-16. 2003
Venous Thromboembolism and Cancer: Risks and Outcomes. 107:I17-I21. 2003
Unstable Angina and Non–ST-Elevation Myocardial Infarction. 107:2640-2645. 2003
American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. 107:1692-1711. 2003
Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease. 107:1579-1585. 2003
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. 107:1284-1290. 2003
Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study. 107:960-965. 2003
Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes. 107:966-972. 2003
Effects of AGI-1067 and probucol after percutaneous coronary interventions.. 107:552-558. 2003
Multiple Infections and Subsequent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study. 107:251-257. 2003
Effect of Cardiac Resynchronization on Myocardial Efficiency and Regional Oxidative Metabolism. 107:28-31. 2003
A Lifetime of Prevention. 106:2997-2998. 2002
Untitled - Response. 106:E200-E201. 2002
Reasons for Resistance to Aspirin in Cardiovascular Disease. 106:1-2. 2002
Reasons for resistance to aspirin in cardiovascular disease.. 106:e181-e182. 2002
Relationship of Anti-60 kDa Heat Shock Protein and Anti-Cholesterol Antibodies to Cardiovascular Events. 106:2775-2780. 2002
Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups. 106:1622-1626. 2002
Prediction of Long-Term Prognosis in 12 169 Men Referred for Cardiac Rehabilitation. 106:666-671. 2002
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib. 106:e18. 2002
Antithrombin-Heparin Covalent Complex. 106:261-265. 2002
Ramipril and cardiovascular risk reduction - Response. 105:A194-A195. 2002
Heterogeneity in the Management and Outcomes of Patients With Acute Myocardial Infarction Complicated by Heart Failure. 105:2605-2610. 2002
A pill for every ill - Response. 105:E82-E82. 2002
Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events. 105:1650-1655. 2002
Direct Thrombin Inhibitors in Acute Coronary Syndromes. 105:1004-1011. 2002
Effect of ramipril and vitamin E on atherosclerosis - Response. 105:E5-E6. 2002
Global Burden of Cardiovascular Diseases. 104:2855-2864. 2001
Global Burden of Cardiovascular Diseases. 104:2746-2753. 2001
Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator. 104:1622-1626. 2001
Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril. 104:1615-1621. 2001
Effects of Ramipril on Coronary Events in High-Risk Persons. 104:522-526. 2001
Stroke in Relation to Cardiac Procedures in Patients With Non–ST-Elevation Acute Coronary Syndrome. 104:269-274. 2001
Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement. 104:74-78. 2001
Relationship Between Pacemaker Dependency and the Effect of Pacing Mode on Cardiovascular Outcomes. 103:3081-3085. 2001
Guide to Anticoagulant Therapy: Heparin. 103:2994-3018. 2001
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia. 103:1838-1843. 2001
Cost-Effectiveness of the Implantable Cardioverter-Defibrillator. 103:1416-1421. 2001
Effects of Ramipril and Vitamin E on Atherosclerosis. 103:919-925. 2001
Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation. 103:643-650. 2001
Treatment of Proximal Deep Vein Thrombosis With a Novel Synthetic Compound (SR90107A/ORG31540) With Pure Anti–Factor Xa Activity. 102:2726-2731. 2000
The Effects of β ₁ -Blockade on Oxidative Metabolism and the Metabolic Cost of Ventricular Work in Patients With Left Ventricular Dysfunction. 102:2070-2075. 2000
Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis. 102:1748-1754. 2000
Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction. 102:1014-1019. 2000
Identification of Patients Most Likely to Benefit From Implantable Cardioverter-Defibrillator Therapy. 101:1660-1664. 2000
Canadian Implantable Defibrillator Study (CIDS). 101:1297-1302. 2000
Effects of Metoprolol CR in Patients With Ischemic and Dilated Cardiomyopathy. 101:378-384. 2000
Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction. 100:1593-1601. 1999
Plasma Urokinase Antigen and Plasminogen Activator Inhibitor-1 Antigen Levels Predict Angiographic Coronary Restenosis. 100:1616-1622. 1999
ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: Executive Summary and Recommendations. 100:1464-1480. 1999
Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure. 100:1056-1064. 1999
Influence of pre-PTCA strategy and initial PTCA result in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI).. 100:910-917. 1999
Primary Stenting Versus Balloon Angioplasty in Occluded Coronary Arteries. 100:236-242. 1999
Vasoflux, a New Anticoagulant With a Novel Mechanism of Action. 99:682-689. 1999
Impact of managed waiting for coronary artery bypass graft surgery on patients' perceived quality of life.. 98:II29-II33. 1998
Quality of life in patients with bioprostheses and mechanical prostheses. Evaluation of cohorts of patients aged 51 to 65 years at implantation.. 98:II81-II86. 1998
Low-Molecular-Weight Heparin. 98:1575-1582. 1998
Long-Term Oral Anticoagulant Therapy in Patients With Unstable Angina or Suspected Non–Q-Wave Myocardial Infarction. 98:1064-1070. 1998
Induction of Cyclooxygenase-2 and Activation of Nuclear Factor-κB in Myocardium of Patients With Congestive Heart Failure. 98:100-103. 1998
Indications for ACE Inhibitors in the Early Treatment of Acute Myocardial Infarction. 97:2202-2212. 1998
Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients. 97:1702-1707. 1998
Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].. 97:1702-1707. 1998
Emerging Epidemic of Cardiovascular Disease in Developing Countries. 97:596-601. 1998
Thrombin Binds to Soluble Fibrin Degradation Products Where it Is Protected From Inhibition by Heparin-Antithrombin but Susceptible to Inactivation by Antithrombin-Independent Inhibitors. 97:544-552. 1998
Guidelines for use of anticoagulants - Response. 96:2099-2099. 1997
Comparison of the Effects of Two Doses of Recombinant Hirudin Compared With Heparin in Patients With Acute Myocardial Ischemia Without ST Elevation. 96:769-777. 1997
Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease. 96:61-68. 1997
Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Collaborative Organization for RheothRx Evaluation (CORE).. 96:192-201. 1997
Effect of Nonspecific Binding to Plasma Proteins on the Antithrombin Activities of Unfractionated Heparin, Low-Molecular-Weight Heparin, and Dermatan Sulfate. 95:118-124. 1997
Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review. 94:3026-3049. 1996
Comparison of High-Dose With Low-Dose Aspirin in Patients With Mechanical Heart Valve Replacement Treated With Oral Anticoagulant. 94:2113-2116. 1996
Fish Oils and Low-Molecular-Weight Heparin for the Reduction of Restenosis After Percutaneous Transluminal Coronary Angioplasty. 94:1553-1560. 1996
Calcium antagonists in coronary disease and hypertension - Response. 94:1143-1143. 1996
Calcium antagonists in coronary disease and hypertension.. 94:1142-1143. 1996
Prognostic Significance of Plasma Norepinephrine in Patients With Asymptomatic Left Ventricular Dysfunction. 94:690-697. 1996
Dual-Chamber Versus Ventricular Pacing. 94:578-583. 1996
Management of Deep Vein Thrombosis and Pulmonary Embolism. 93:2212-2245. 1996
Cost of Prevention. 93:1774-1776. 1996
Activated Partial Thromboplastin Time and Outcome After Thrombolytic Therapy for Acute Myocardial Infarction. 93:870-878. 1996
Heart Rate Variability. 93:1043-1065. 1996
Low-Molecular-Weight Heparinoid Orgaran Is More Effective Than Aspirin in the Prevention of Venous Thromboembolism After Surgery for Hip Fracture. 93:80-84. 1996
Prolonged Antithrombin Activity of Low-Molecular-Weight Heparins. 92:2819-2824. 1995
STEROID INHIBITION OF CYTOKINE-MEDIATED VASODILATION AFTER WARM HEART-SURGERY. 92:347-353. 1995
Steroid Inhibition of Cytokine-Mediated Vasodilation After Warm Heart Surgery. 92:347-353. 1995
Calcium Antagonists in Coronary Artery Disease and Hypertension. 92:1079-1082. 1995
Hirulog in the Treatment of Unstable Angina. 92:727-733. 1995
A Novel and Rapid Whole-Blood Assay for D-Dimer in Patients With Clinically Suspected Deep Vein Thrombosis. 91:2184-2187. 1995
Redistribution of Myocardial Blood Flow With Topical Nitroglycerin in Patients With Coronary Artery Disease. 91:1381-1388. 1995
Does PTCA in Acute Myocardial Infarction Affect Mortality and Reinfarction Rates?. 91:476-485. 1995
CARDIOPULMONARY BYPASS, TEMPERATURE, AND CENTRAL-NERVOUS-SYSTEM DYSFUNCTION. 90:250-255. 1994
Cardiopulmonary bypass, temperature, and central nervous system dysfunction.. 90:II250-II255. 1994
Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.. 90:2385-2389. 1994
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.. 90:2056-2069. 1994
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.. 89:1449-1468. 1994
Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association.. 89:1469-1480. 1994
Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.. 88:2277-2283. 1993
HEPARIN-BINDING PROTEINS - CONTRIBUTION TO HEPARIN REBOUND AFTER CARDIOPULMONARY BYPASS. 88:420-425. 1993
Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass.. 88:II420-II425. 1993
Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. SOLVD Investigators.. 88:481-491. 1993
DESIGN, RESULTS, AND INTERPRETATION OF RANDOMIZED, CONTROLLED TRIALS IN CONGESTIVE-HEART-FAILURE AND LEFT-VENTRICULAR DYSFUNCTION. 87:115-121. 1993
Intravenous magnesium in acute myocardial infarction. An effective, safe, simple, and inexpensive intervention.. 87:2043-2046. 1993
CARDIAC MECHANICS DURING DEVELOPMENT OF HEART-FAILURE. 87:14-20. 1993
Cardiac mechanics during development of heart failure. SOLVD Investigators.. 87:IV14-IV20. 1993
Amiodarone for patients with ventricular premature depolarizations after myocardial infarction. Is it safe to stop treatment at one year?. 87:637-639. 1993
Design, results, and interpretation of randomized, controlled trials in congestive heart failure and left ventricular dysfunction. 87. 1993
Oral anticoagulant therapy. Urgent need for standardization.. 86:1332-1335. 1992
Report of the Conference on Low Blood Cholesterol: Mortality Associations.. 86:1046-1060. 1992
Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.. 86:431-438. 1992
Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland.. 85:2337-2344. 1992
Antiarrhythmics and VPD suppression.. 84:928-930. 1991
Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study.. 84:550-557. 1991
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).. 82:1724-1729. 1990
Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction.. 82:1668-1674. 1990
ROUTINE MEDICAL-MANAGEMENT OF ACUTE MYOCARDIAL-INFARCTION - LESSONS FROM OVERVIEWS OF RECENT RANDOMIZED CONTROLLED TRIALS. 82:117-134. 1990
Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials.. 82:II117-II134. 1990
Effect of acute angiotensin converting enzyme inhibition on left ventricular filling in patients with congestive heart failure. Relation to right ventricular volumes.. 81:III115-III122. 1990
AHA Conference Report on Cholesterol. Intervention studies.. 80:739-743. 1989
WORKSHOP .5. INTERVENTION STUDIES. 80:739-743. 1989
An overview of randomized trials of rehabilitation with exercise after myocardial infarction.. 80:234-244. 1989
Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction.. 79:610-619. 1989
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.. 79:8-15. 1989
Doppler color-flow imaging assessment of shunt size in atrial septal defect.. 78:522-528. 1988
Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator.. 77:1311-1315. 1988
Increased sensitivity of the denervated transplanted human heart to isoprenaline both before and after beta-adrenergic blockade.. 75:696-704. 1987
The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease.. 75:124-130. 1987
DOES THERAPY DIRECTED BY PROGRAMMED ELECTRICAL-STIMULATION PROVIDE A SATISFACTORY CLINICAL-RESPONSE. 73:59-66. 1986
Does therapy directed by programmed electrical stimulation provide a satisfactory clinical response?. 73:II59-II66. 1986
Digitalis--a new controversy regarding an old drug. The pitfalls of inappropriate methods.. 73:14-18. 1986
A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits.. 72:178-182. 1985
MORBIDITY AND MORTALITY IN MITRAL-VALVE SURGERY. 72:120-128. 1985
Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction.. 67:I32-I41. 1983
The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge.. 67:901-906. 1983
Platelet tests and antiplatelet drugs in coronary artery disease.. 67:500-504. 1983
REDUCTION IN INFARCT SIZE, ARRHYTHMIAS AND CHEST PAIN BY EARLY INTRAVENOUS BETA-BLOCKADE IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION. 67:32-41. 1983
Platelet release and thromboxane synthesis in symptomatic coronary artery disease.. 66:327-333. 1982
Selective and nonselective beta-adrenoceptor blockade in hypertension: responses to changes in posture, cold and exercise.. 65:1171-1177. 1982
Intravenous hyaluronidase therapy for myocardial infarction in man: double-blind trial to assess infarct size limitation.. 65:764-771. 1982
Determinants of myocardial hemorrhage after coronary reperfusion in the anesthetized dog.. 65:62-69. 1982
Process versus outcome in hypertension: a positive result.. 65:28-33. 1982
Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis.. 64:622-625. 1981
Clinical trial of low-dose heparin for the prevention of stroke progression. 62. 1980
Sex-related differences in platelet function in vivo following aspirin administration. 62. 1980
The inhibitory effect of aspirin platelet function independent of acetylation of cyclo oxygenase. 62. 1980
The relationship between the hemorrhagic and antithrombotic effects of standard and low molecular weight (LMW) heparins. 62. 1980
The extraction of circulating catecholamines by the lungs in normal man and in patients with pulmonary hypertension.. 60:160-163. 1979
Catecholamines in coronary sinus and peripheral plasma during pacing-induced angina in man.. 59:37-43. 1979
Myocardial infarction size from serial CPK: variability of CPK serum entry ratio with size and model of infarction.. 58:1143-1153. 1978
Impedance plethysmography: the relationship between venous filling and sensitivity and specificity for proximal vein thrombosis.. 58:898-902. 1978
Exercise tests and ST changes.. 58:757. 1978
Comparison of the electrocardiographic changes induced by maximam exercise testing with treadmill and cycle ergometer.. 57:1066-1070. 1978
Comparative effects of sodium and calcium heparin on plasma heparin concentration, partial thromboplastin time, platelet count and bleeding. 58. 1978
Experience with bretylium tosylate by a hospital cardiac arrest team.. 55:541-544. 1977
Heparin kinetics in venous thrombosis and pulmonary embolism.. 53:691-695. 1976
Impedance plethysmography using the occlusive cuff technique in the diagnosis of venous thrombosis.. 53:696-700. 1976
Studies of the interaction of heparin with thrombin and antithrombin III using affinity chromatographic techniques. 54. 1976
The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis.. 52:497-499. 1975
Letter: Techniques of measuring regional wall motion.. 51:395-396. 1975
Experience with bretylium tosylate by a mobile resuscitation team. 52. 1975
Regional Left Ventricular Performance. 47:1400-1400. 1973
Mechanisms of Angina in Aortic Stenosis. 36:480-488. 1967
Syphilitic Aortitis. 29:346-355. 1964
Changes in Serum Lipids in Relation to Emotional Stress during Rigid Control of Diet and Exercise. 26:379-387. 1962
Platelets, blood flow, and the vessel wall 1990

Circulation Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)